Preferred Stock Purchase Agreement



 Exhibit 10.1 
 PREFERRED STOCK PURCHASE AGREEMENT 
 This
Preferred Stock Purchase Agreement (“Agreement”) is entered into and effective as of December 3, 2009 (“Effective Date”), by and among ImmunoCellular Therapeutics, Ltd., a Delaware corporation
(“Company”), and Socius Capital Group, LLC, a Delaware limited liability company, dba Socius Life Sciences Capital Group, LLC (including its designees, successors and assigns, “Investor”). 
 RECITALS 
 A. The parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue to Investor, and Investor shall purchase from the Company, from time to time as provided herein, up to $10,000,000.00 of
shares of Series A Preferred Stock; and 
 B. The offer and sale of the Securities provided for herein are being made without
registration under the Act (as defined below), in reliance upon the provisions of Section 4(2) of the Act, Regulation D promulgated under the Act, and such other exemptions from the registration requirements of the Act as may be available with
respect to any or all of the purchases of Securities to be made hereunder. 
 AGREEMENT 
 In consideration of the premises, the mutual provisions of this Agreement, and other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, Company and Investor agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Certificate of Designations, and (b) the following terms have
the meanings indicated in this ARTICLE 1: 
 “Act” means the Securities Act of 1933, as amended.

 “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Act. With respect to Investor, without limitation, any Person owning, owned by, or under common ownership with Investor, and
any investment fund or managed account that is managed on a discretionary basis by the same investment manager as Investor will be deemed to be an Affiliate. 
 “Agreement” means this Preferred Stock Purchase Agreement. 
 “Bloomberg” means Bloomberg Financial Markets. 
 “Change in Control” has the meaning
set forth within the definition of Fundamental Transaction, below. 







 “Certificate of Designations” means the certificate to be filed with the
Secretary of State of the State of Delaware, in the form attached hereto as Exhibit B. 
 “Closing”
means any one of (i) the Commitment Closing and (ii) each Tranche Closing. 
 “Closing Bid Price” and
“Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Trading Market, as reported by Bloomberg, or, if the Trading Market begins
to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00 p.m., Eastern time, as
reported by Bloomberg, or, if the Trading Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or
trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic
bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market
makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any
of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and Investor. If the Company and Investor are unable to
agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 6.7. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during the applicable calculation period. 
 “Commitment Closing” has the meaning set forth in
Section 2.2(a). 
 “Commitment Fee” means a non-refundable fee of $500,000.00, payable by Company
to Investor as follows: (i) $250,000.00 on the first Tranche Notice Date, and (ii) $250,000.00 on the Tranche Closing Date at which the aggregate Tranche Purchase Price for all Tranche Shares purchased to date (including Tranche Shares to
be purchased on such Tranche Closing Date) equals at least $5,000,000.00. Each installment of the Commitment Fee shall be payable at the Company’s election either (a) in cash or by wire transfer of immediately available funds to an account
designated by Investor, or (b) by issuance and delivery of shares of Common Stock registered for resale and freely tradable, and valued based upon the lower of (1) 90% of the VWAP for the Common Stock on the 5 Trading Days immediately
preceding the Effective Date, or (2) 90% of the VWAP for the Common Stock on the 5 Trading Days immediately preceding the share delivery date. If not earlier paid, the $250,000.00 portion of the Commitment Fee described in clause (i) above
shall be due and payable on the six-month anniversary of the effective date of the Registration Statement whether or not any Tranche Closings have then occurred. The $250,000 portion of the Commitment Fee described in clause (ii) above will not
be payable unless and until the condition described in clause (ii) has been satisfied. 
 “Commitment Fee
Shares” means shares of the Company’s Common Stock issued by the Company to Investor in accordance with Section 2.1. 
  

 2 








 “Common Shares” means the Warrant Shares and any shares of Common Stock
issued as the Commitment Fee. 
 “Common Stock” means the common stock, par value $0.0001 per share, of the
Company, and any replacement or substitute thereof, or any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock. 
 “Company Termination” has the meaning set forth in Section 3.2. 
 “Delisting Event” means any time during the term of this Agreement, that the Common Stock is not listed for and regularly
trading on a Trading Market, or is suspended or delisted with respect to the trading of the shares of Common Stock on a Trading Market. 
 “Disclosure Schedules” means the disclosure schedules of the Company delivered concurrently herewith, attached hereto, and incorporated herein by reference. The Disclosure Schedules shall
contain no material non-public information. 
 “DTC” means The Depository Trust Company, or any successor
performing substantially the same function for Company. 
 “DWAC Shares” means, following the earlier of
effectiveness of the Registration Statement or the six-month anniversary of issuance, all Common Shares or other shares of Common Stock issued or issuable to Investor or any Affiliate, successor or assign of Investor pursuant to any of the
Transaction Documents, including without limitation any Warrant Shares, all of which shall be (a) issued in electronic form, (b) freely tradable and without restriction on resale, and (c) timely credited by Company to the specified
Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar program hereafter adopted by DTC performing substantially the same function, in accordance with irrevocable
instructions issued to and countersigned by the Transfer Agent, in the form attached hereto as Exhibit C or in such other form agreed upon by the parties.  
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Fundamental Transaction” means and shall be deemed to have occurred at such time upon any of the following events: 
 (i) a consolidation, merger or other business combination or event or transaction following which the holders of Common Stock immediately preceding such consolidation, merger, combination or event either
(a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company (a “Change in Control”); 
 (ii) the sale or transfer of all or substantially all of the Company’s assets, other than in the ordinary course of business; or

 (iii) a purchase, tender or exchange offer made to the holders of the outstanding shares of Common Stock that is accepted by
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to such purchase, tender or exchange
offer). 
  

 3 








 “GAAP” means United States generally accepted accounting principles applied
on a consistent basis during the periods involved. 
 “Indebtedness” means (a) any liabilities for
borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others,
whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (c) the present value of any lease payments in excess of $100,000 due under leases required to be capitalized in accordance with GAAP. 
 “Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. 
 “Material Adverse Effect” means any material adverse effect on (i) the legality, validity or enforceability of any
Transaction Document, (ii) the results of operations, assets, business, prospects or financial condition of the Company and the Subsidiaries, taken as a whole, or (iii) a the Company’s ability to perform in any material respect on a
timely basis its obligations under any Transaction Document; provided, however, that none of the following, individually or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred: (a) changes
in conditions in the U.S. or global capital, credit or financial markets generally, including changes in the availability of capital or currency exchange rates; (b) changes generally affecting the biotechnology or pharmaceutical industries;
(c) any deterioration in the results of operations, assets, business or financial condition of the Company substantially resulting from (1) circumstances, conditions or risks (including, without limitation, the section entitled “Risk
Factors” contained in the Company’s Form 10-K for its fiscal year ended December 31, 2008) existing as of the Effective Date that are set forth in any of the SEC Reports or (2) any of the matters set forth in the Disclosure
Schedule (as the same may be updated pursuant to Section 2.3(c)(ii)); (d) any effect of the announcement of this Agreement or the consummation of the transactions contemplated by this Agreement on the Company’s relationships,
contractual or otherwise, with customers, suppliers, vendors, bank lenders, strategic venture partners or employees; and (e) any decrease in the market price of the Common Stock (but excluding herefrom any condition, occurrence, state of facts
or event underlying such decrease to the extent that such condition, occurrence, state of facts or event otherwise would constitute a Material Adverse Effect). 
 “Material Agreement” means any material loan agreement, financing agreement, equity investment agreement or securities instrument to which Company is a party, any agreement or instrument
to which Company and Investor or any Affiliate of Investor is a party, and any other material agreement listed, or required to be listed, on any of Company’s reports filed or required to be filed with the SEC, including without limitation Forms
10-K, 10-Q or 8-K. 
  

 4 








 “Maximum Placement” means $10,000,000.00. 
 “Maximum Tranche Amount” means, subject to any other applicable limitations set forth in this Agreement, the Maximum
Placement less the amount of any previously noticed and funded Tranches. 
 “Officer’s Closing
Certificate” means a certificate in customary form reasonably acceptable to Investor, executed by an authorized officer of the Company. 
 “Opinion” means an opinion from Company’s independent legal counsel, in the form attached as Exhibit D or in such other form agreed upon by the parties, to be delivered in
connection with the Commitment Closing and any Tranche Closing. 
 “Person” means an individual or corporation,
partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
 “Preferred Shares” means shares of Series A Preferred Stock of the Company provided for in the Certificate of Designations,
to be issued to Investor pursuant to this Agreement. 
 “Prospectus” includes each prospectus and prospectus
supplement (within the meaning of the Act) related to the sale or offering of any Common Shares, including without limitation any prospectus or prospectus supplement contained within the Registration Statement. 
 “Registration Statement” means a valid, current and effective registration statement registering for resale the Common
Shares, and except where the context otherwise requires, means such registration statement, as amended, including (i) all documents filed as a part thereof or incorporated by reference therein, and (ii) any information contained or
incorporated by reference in a prospectus filed with the SEC in connection with such registration statement, to the extent such information is deemed under the Act to be part of such registration statement. 
 “Regulation D” means Regulation D promulgated under the Act. 
 “Required Approval” means any approval of the Trading Market or the Company’s stockholders required to be obtained by
Company prior to issuing the Securities pursuant to any applicable rules of the Trading Market. 
 “Required Tranche
Documents” has the meaning set forth in Section 2.3(e). 
 “Rule 144” means Rule 144
promulgated by the SEC pursuant to the Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect. 
 “Rule 144 Eligible” means eligible for immediate resale under Rule 144 without limitation on the amount of securities sold
under Rule 144(e) and without requiring discharge by payment in full of any promissory notes given to the Company prior to the sale of the securities under Rule 144(d)(2)(iii). 
  

 5 








 “SEC” means the United States Securities and Exchange Commission.

 “SEC Reports” includes all reports required to be filed by the Company under the Act and/or the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the Effective Date (or such shorter period as the Company was required by law to file such material). 
 “Securities” includes the Warrant, the Common Shares and the Preferred Shares issuable pursuant to this Agreement.

 “Subsidiary” means any Person the Company owns or controls, or in which the Company, directly or indirectly,
owns a majority of the capital stock or similar interest that would be disclosable pursuant to Regulation S-K, Item 601(b)(21). 
 “Termination” has the meaning set forth in Section 3.1. 
 “Termination
Date” means the earlier of (i) the date that is the two-year anniversary of the Effective Date, or (ii) the Tranche Closing Date on which the sum of the aggregate Tranche Purchase Price for all Tranche Shares equals the Maximum
Placement. 
 “Termination Notice” has the meaning as set forth in Section 3.2. 
 “Trading Day” means any day on which the Common Stock is traded on the Trading Market; provided that it shall not include
any day on which the Common Stock is (a) scheduled to trade for less than 5 hours, or (b) suspended from trading. 
 “Trading Market” means the OTC Bulletin Board, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE Amex, or the New York Stock Exchange, whichever is at the time the principal
trading exchange or market for the Common Stock, but does not include the Pink Sheets inter-dealer electronic quotation and trading system. 
 “Tranche” has the meaning set forth in Section 2.3. 
 “Tranche Amount” means the amount of any individual purchase of Preferred Shares under this Agreement, as specified by the Company, and shall not exceed the Maximum Tranche Amount. 
 “Tranche Closing” has the meaning set forth in Section 2.3(f). 
 “Tranche Closing Date” has the meaning set forth in Section 2.3(f). 
 “Tranche Notice” has the meaning set forth in Section 2.3(b). 
 “Tranche Notice Date” has the meaning set forth in Section 2.3(b). 
 “Tranche Purchase Price” has the meaning set forth in Section 2.3(b), and shall be specified in writing by the
Company. 
  

 6 








 “Tranche Share Price” means $10,000.00 per Preferred Share. The Company may
not issue fractional Preferred Shares. 
 “Tranche Shares” means the Preferred Shares that are purchased by
Investor pursuant to a Tranche. For the Maximum Placement, the Company shall issue 1,000 Preferred Shares to Investor. 
 “Transaction Documents” means this Agreement, the other agreements and documents referenced herein, and the exhibits and schedules hereto and thereto. 
 “Transfer Agent” means Computershare Trust Company, N.A., or any successor transfer agent for the Common Stock. 

“Use of Proceeds Certificate” means a certificate, in substantially the form attached as Exhibit E, signed by an
officer of the Company, setting forth how the Tranche Purchase Price will be applied by the Company. 
 “VWAP”
means, for any date, the volume-weighted average price, calculated by dividing the aggregate value of Common Stock traded on the Trading Market (price multiplied by number of shares traded) by the total volume (number of shares) of Common Stock
traded on the Trading Market for such date, or the nearest preceding Trading Day. 
 “Warrant Shares” means the
shares of Common Stock issuable upon exercise of the Warrants. 
 “Warrant” means the Warrant issuable under
this Agreement, in the form attached hereto as Exhibit A, to purchase shares of Common Stock with an aggregate exercise price equal to up to $13,500,000.00. 
 ARTICLE 2 
 PURCHASE AND SALE 
 2.1 Agreement to Purchase. Subject to the terms and conditions herein and the satisfaction of the conditions to closing set
forth in this ARTICLE 2: 
 (a) Investor hereby agrees to purchase such amounts of Preferred Shares as the Company
may, in its sole and absolute discretion, from time to time elect to issue and sell to Investor according to one or more Tranches pursuant to Section 2.3 below; and 
 (b) The Company agrees to pay the Commitment Fee and to issue the Preferred Shares, the Common Shares, and the Warrant to Investor as
provided herein. 
 (c) The Company agrees to pay $250,000.00 of the aggregate Commitment Fee of $500,000.00 on the first
Tranche Notice Date. This portion of the Commitment Fee shall be paid to Investor at the Company’s election either (i) in cash or by wire transfer of immediately available funds to an account designated by Investor or (ii) by issuance
and delivery to Investor of the Commitment Fee Shares, with such shares to be issued and delivered in accordance with the provisions of Sections 2.1(e) and 2.1(f). 
  

 7 








 (d) The Company agrees to pay the second $250,000.00 of the Commitment Fee on the
Tranche Closing Date at which the aggregate Tranche Purchase Price for all purchased Tranche Shares to date (including Tranche Shares to be purchased on such Tranche Closing Date) equals at least $5,000,000.00. The second $250,000.00 of the
Commitment Fee shall be paid to Investor at the Company’s election either (i) in cash or by wire transfer of immediately available funds to an account designated by Investor or (ii) by issuance and delivery to Investor of the
Commitment Fee Shares, with such shares to be issued and delivered in accordance with the provisions of Sections 2.1(e) and 2.1(f). The Company shall have no obligation to pay the second $250,000.00 portion of the Commitment Fee unless and until the
aggregate Tranche Purchase Price for all purchased Tranche Shares to date equals at least $5,000,000.00. 
 (e) On the
Effective Date, the Company shall issue to Investor, by delivery into escrow as described herein, and as an estimate of the maximum number of Commitment Fee Shares to which Investor may become entitled under this Agreement, 1,200,000 Commitment Fee
Shares (which are subject to cancellation as described in this Section 2.1(e)). The Commitment Fee Shares issued on the Effective Date shall be evidenced by two stock certificates, with each certificate representing fifty percent (50%) of
the 1,200,000 total Commitment Fee Shares (with the shares covered by each such certificate subject to adjustment on the date that the Commitment Fee Shares are actually delivered to Investor). The stock certificates evidencing the Commitment Fee
Shares shall be held in escrow by the Company and shall bear a legend referring to restrictions on transfer imposed by the Act, such legend to be substantially in the form of the legend set forth in Section 5.1(b). If the Company elects
pursuant to Section 2.1(c) or Section 2.1(d) to pay the first or second $250,000.00 installment of the Commitment Fee in cash or by wire transfer of immediately available funds, the applicable portion of the Commitment Fee Shares shall be
cancelled effective as of the Company’s delivery of such funds, and Investor shall thereafter have no right to any of the cancelled Commitment Fee Shares. Furthermore, if this Agreement is terminated by Investor pursuant to Section 3.1 or
by the Company pursuant to Section 3.2, in either case prior to the date that Investor is entitled to receive the second $250,000.00 installment of the Commitment Fee, then that portion of the Commitment Fee Shares that were not earned prior to
the termination date shall be cancelled effective as of the termination of this Agreement and Investor shall thereafter have no right to any of the cancelled Commitment Fee Shares. 
 (f) Investor shall be entitled to receive the Commitment Fee Shares and the certificates evidencing the Commitment Fee Shares if, but
only if, the Company elects to pay the applicable portion of the Commitment Fee in Commitment Fee Shares rather than in cash or by wire transfer of immediately available funds. If Investor becomes entitled to receive any of the Commitment Fee Shares
pursuant to the preceding sentence, the Company shall deliver to Investor, at such Tranche Notice Date or Tranche Closing Date, as applicable, the certificate evidencing the applicable portion of the Commitment Fee Shares (or, if the number of
shares required to be issued as Commitment Fee Shares pursuant to the definition of “Commitment Fee” set forth in Article I is not then equal to the number set forth on the certificate, a replacement certificate for the correct number of
Commitment Fee Shares shall be delivered to Investor and the original certificate held in escrow shall be cancelled). The legend described in Section 2.1(e) on such certificate shall be removed, and the Commitment Fee Shares shall be delivered
as DWAC Shares, on the date that Investor is entitled to receive the Commitment Fee

  

 8 








 
Shares out of the escrow. Prior to the date that Investor is entitled to receive the Commitment Fee Shares pursuant to the preceding provisions of this Section 2.1(f), Investor shall not be
entitled to sell, pledge, assign or otherwise transfer any of the Commitment Fee Shares. A total of 1,200,000 shares of Common Stock shall be included in the Registration Statement for use by the Company in satisfaction of the Commitment Fee. Any
such shares that are registered for resale but are not used in payment of the Commitment Fee shall be cancelled by the Company. 
 (g) The Company shall hold the Commitment Fee Shares in escrow pursuant to this Section 2.1, and shall deliver the Commitment Fee Shares to Investor, if required hereby, strictly in compliance herewith. Pending delivery
to Investor or release to the Company for cancellation, as applicable, one or more certificates evidencing the Commitment Fee Shares, titled in the name of Investor or its designee as instructed by Investor, shall be held in the escrow, with copies
of such certificates delivered to Investor on the Effective Date. The Company may not sell or otherwise transfer the Commitment Fee Shares to any third party. In the event of any dispute related to the Commitment Fee Shares, the Company shall keep
the disputed Commitment Fee Shares in the escrow until resolution of the dispute by written agreement of the parties or by a court of competent jurisdiction in accordance with Section 6.7. 
 2.2 Investment Commitment 
 (a) Investment Commitment. The closing of this Agreement (the “Commitment Closing”) shall be deemed to occur when this Agreement has been duly executed by both Investor and
the Company, and the other Conditions to the Commitment Closing set forth in Section 2.2(b) have been met. 
 (b)
Conditions to Investment Commitment. As a condition precedent to the Commitment Closing, all of the following (the “Conditions to Commitment Closing”) shall have been satisfied prior to or concurrently with the
Company’s execution and delivery of this Agreement: 
 (i) the following documents shall have been delivered to
Investor: (A) this Agreement, executed by the Company; (B) a Secretary’s Certificate as to (x) the resolutions of the Company’s board of directors authorizing this Agreement and the Transaction Documents, and the
transactions contemplated hereby and thereby, (y) a copy of the Company’s current Certificate or Articles of Incorporation, and (z) a copy of the Company’s current Bylaws; (C) the Certificate of Designations executed by the
Company and accepted by the Secretary of State of Delaware; (D) the Opinion; and (E) a copy of (1) the Company’s press release (if any) announcing the transactions contemplated by this Agreement; and (F) a copy of the
Company’s Current Report on Form 8-K, as filed with the SEC, describing the transaction contemplated by, and attaching a complete copy of, the Transaction Documents; 
 (ii) other than for losses incurred in the ordinary course of business, there has not been any Material Adverse Effect on the
Company since the date of the last SEC Report filed by the Company, including but not limited to incurring material liabilities; 
 (iii) the representations and warranties of the Company in this Agreement shall be true and correct in all material respects and the Company shall have delivered an Officer’s Closing Certificate to such effect to Investor,
signed by an officer of the Company; 
  

 9 








 (iv) the Warrant to purchase shares of Common Stock with an aggregate exercise price
equal to up to $13,500,000.00 shall have been delivered to Investor; 
 (v) the Commitment Fee Shares shall have been
delivered to Investor in escrow pursuant to Section 2.1(e)-(g); and 
 (vi) any Required Approval has been
obtained. 
 (c) Investor’s Obligation to Purchase. Subject to the prior satisfaction of all conditions set
forth in this Agreement, following Investor’s receipt of a validly delivered Tranche Notice, Investor shall be required to purchase from the Company a number of Tranche Shares equal to the permitted Tranche Share Amount, in the manner described
below. 
 2.3 Tranches to Investor 
 (a) Procedure to Elect a Tranche. Subject to the Maximum Tranche Amount, the Maximum Placement and the other conditions and limitations set forth in this Agreement, at any time beginning on
the effective date of the Registration Statement, the Company may, in its sole and absolute discretion, elect to exercise one or more individual purchases of Preferred Shares under this Agreement (each a “Tranche”) according to the
following procedure. 
 (b) Delivery of Tranche Notice. The Company shall deliver an irrevocable written notice
(the “Tranche Notice”), in the form attached hereto as Exhibit F, to Investor stating that the Company shall exercise a Tranche and stating the number of Preferred Shares which the Company will sell to Investor at the Tranche
Share Price, and the aggregate purchase price for such Tranche (the “Tranche Purchase Price”). A Tranche Notice delivered by the Company to Investor by 4:30 p.m. Eastern time on any Trading Day shall be deemed delivered on the same
day. A Tranche Notice delivered by the Company to Investor after 4:30 p.m. Eastern time on any Trading Day, or at any time on a non-Trading Day, shall be deemed delivered on the next Trading Day. The date that the Tranche Notice is deemed delivered
is the “Tranche Notice Date”. Each Tranche Notice shall be delivered via facsimile or electronic mail, with confirming copy by overnight carrier, in each case to the address set forth in Section 6.2. Except for the first
Tranche Closing, the Company may not give a Tranche Notice unless the Tranche Closing for the prior Tranche has occurred or has been cancelled by the Company pursuant to Section 2.3(g). 
 (c) Warrant. Any portion of the Warrant that becomes exercisable in connection with the delivery of a Tranche Notice and
exercised by Investor in accordance with Section 1.1 of the Warrant shall be deemed exercised (i) on the applicable Tranche Notice Date, if the Company receives the Exercise Delivery Documents from Investor by 6:30 p.m. Eastern time
on the Tranche Notice Date, or (ii) on the next Trading Day, if the Company receives the Exercise Delivery Documents from Investor after 6:30 p.m. Eastern Time on the applicable Tranche Notice Date or on any subsequent date. 
  

 10 








 (d) Conditions Precedent to Right to Deliver a Tranche Notice. The right of
the Company to deliver a Tranche Notice is subject to the satisfaction (or written waiver by Investor in its sole discretion), on the date of delivery of such Tranche Notice, of each of the following conditions: 
 (i) the Common Stock (including without limitation any shares of Common Stock that may be issued to the Investor in payment of the
Commitment Fee) shall be listed for and currently trading on the Trading Market, and to the Company’s knowledge there is no notice of any suspension or delisting with respect the trading of the shares of Common Stock on such Trading Market;

 (ii) the representations and warranties of the Company set forth in this Agreement shall be true and correct in all
material respects as if made on such date (except for representations and warranties that are expressly made as of a particular date in which case, such representations and warranties shall be true and correct as of such particular date), and no
material default shall have occurred under this Agreement, or any other agreement with Investor or any Affiliate of Investor, or any other Material Agreement, and the Company shall deliver an Officer’s Closing Certificate to such effect to
Investor, signed by an officer of the Company; 
 (iii) other than losses incurred in the ordinary course of business,
there has been no Material Adverse Effect on the Company since the Commitment Closing; 
 (iv) the Company is not, and
will not be as a result of the applicable Tranche, in material default of this Agreement or any other agreement with Investor or any Affiliate of Investor or any other Material Agreement; 
 (v) there is not then in effect any law, rule or regulation prohibiting or restricting the transactions contemplated in this
Agreement or any other Transaction Document, or requiring any consent or approval which shall not have been obtained, nor is there any pending or threatened proceeding or investigation which may have the effect of prohibiting or adversely affecting
any of the transactions contemplated by this Agreement; no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or adopted by any court or governmental authority of competent
jurisdiction that prohibits the transactions contemplated by this Agreement, and no actions, suits or proceedings shall be in progress, pending or, to the Company’s knowledge threatened, by any person (other than Investor or any Affiliate of
Investor), that seek to enjoin or prohibit the transactions contemplated by this Agreement; 
 (vi) all Common Shares
shall have been timely delivered at the times provided for by this Agreement, including all Warrant Shares issuable pursuant to any Exercise Notice delivered to Company prior to the Tranche Notice Date; 
 (vii) all previously-issued and issuable Common Shares are DWAC Shares, are DTC eligible, and can be immediately converted into
electronic form without restriction on resale; 
 (viii) Company is in compliance with all requirements to maintain its
then-current listing on the Trading Market; 
  

 11 








 (ix) Company has a current, valid and effective Registration Statement permitting
the lawful resale of all previously-issued and issuable Common Shares (including without limitation all Warrant Shares issuable upon exercise of the Warrant delivered in connection with such Tranche and all Commitment Fee Shares); 
 (x) Company has a sufficient number of duly authorized shares of Common Stock reserved for issuance in such amount as may be
required to fulfill its obligations pursuant to the Transaction Documents and any outstanding agreements with Investor and any Affiliate of Investor, including without limitation all Warrant Shares issuable upon exercise of the Warrant issued in
connection with such Tranche; 
 (xi) the aggregate number of Warrant Shares issuable upon exercise of the Warrant
issued on the Tranche Notice Date, when aggregated with all other shares of Common Stock deemed beneficially owned by Investor and its Affiliates whether acquired in connection with the transactions contemplated by the Transaction Documents or
otherwise, would not result in Investor owning more than 9.99% of all Common Stock outstanding on the Tranche Notice Date, as determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder;
and 
 (xii) Investor shall have received the Commitment Fee, except with respect to those Tranche Notices covering
Tranche Purchase Prices aggregating up to $5,000,000.00, Investor shall have received only 50% of the Commitment Fee, and Investor shall have received the balance of the Commitment Fee on the Tranche Closing Date upon which the aggregate Tranche
Purchase Price for all purchased Tranche Shares to date (including shares to be issued on such Tranche Closing Date) equals at least $5,000,000.00. 
 (e) Documents to be Delivered at Tranche Closing. The Closing of any Tranche and Investor’s obligations hereunder shall additionally be conditioned upon the delivery to Investor of each
of the following (the “Required Tranche Documents”) on or before the applicable Tranche Closing Date: 
 (i) a number of Preferred Shares equal to the Tranche Purchase Price divided by the Tranche Share Price shall have been delivered to Investor or an account specified by Investor for the Tranche Shares; 
 (ii) the following executed documents: Opinion and Officer’s Certificate; 
 (iii) a Use of Proceeds Certificate, signed by an officer of the Company, and setting forth how the Tranche Purchase Price will be
applied by the Company; 
 (iv) all Warrant Shares shall have been timely delivered in accordance with any Exercise
Notice delivered to Company prior to the Tranche Closing Date; 
 (v) all documents, instruments and other writings
required to be delivered by the Company to Investor on or before the Tranche Closing Date pursuant to any provision of this Agreement or in order to implement and effect the transactions contemplated herein; 
  

 12 








 (vi) payment of a $5,000.00 non-refundable administrative fee to Investor’s
counsel, by offset against the Tranche Amount, or wire transfer of immediately available funds; and 
 (vii) with
respect to the Tranche Closing at which the remaining 50% of the Commitment Fee is payable, payment of that amount by the Company, which may be offset by Investor against the proceeds due to the Company from the Tranche Purchase Price if the Company
has elected to make this payment in cash. 
 (f) Mechanics of Tranche Closing. 
 (i) Each of the Company and Investor shall deliver all documents, instruments and writings required to be delivered by either of them
pursuant to Section 2.3(e) of this Agreement at or prior to each Tranche Closing. Subject to such delivery and the satisfaction of the conditions set forth in Section 2.3(d) as of the Tranche Closing Date, the closing of the
purchase by Investor of Preferred Shares shall occur by 5:00 p.m. Eastern time, on the date which is 10 Trading Days following (and not counting) the Tranche Notice Date (each a “Tranche Closing Date”) at the offices of Investor.

 (ii) If any portion of the Warrant is exercised by Investor on or after the Tranche Notice Date and prior to or on
the Tranche Closing Date (which exercise shall be effected by Investor sending the Exercise Delivery Documents to the Company in accordance with Section 1.1 of the Warrant), the Company shall send Investor an electronic copy of its share
issuance instructions to the Transfer Agent and shall cause the requisite number of Warrant Shares to be credited to Investor’s account with DTC as DWAC Shares no later than 5:30 p.m. Eastern time on the Trading Day after the date the Company
receives the Exercise Delivery Documents from Investor. If DWAC shares are not credited pursuant to this Section 2.3(f)(ii) by 12:00 p.m. on the Trading Day after the date the Company receives the Exercise Delivery Documents (and including the
circumstance where the Warrant Shares are credited as DWAC Shares by 5:30 p.m. Eastern Time on such Trading Day), then the Tranche Closing Date shall be extended by one Trading Day for each Trading Day that credit of DWAC Shares is not made by 12:00
p.m. 
 (iii) On or before each Tranche Closing Date, Investor shall deliver to the Company, in cash or immediately
available funds, the Tranche Purchase Price to be paid for such Tranche Shares. 
 (iv) The closing (each a
“Tranche Closing”) for each Tranche shall occur on the date that both (i) the Company has delivered to Investor all Required Tranche Documents, and (ii) Investor has delivered to the Company the Tranche Purchase Price.

 (g) Limitation on Obligations to Purchase and Sell. Notwithstanding any other provision, in the event the
Closing Bid Price or Closing Sale Price of the Common Stock during any one or more of the 9 Trading Days following the Tranche Notice Date falls below 75.0% of the Closing Bid Price on the Tranche Notice Date, except as otherwise agreed in writing
between the Company and Investor: (i) the Company may, at its option, and without penalty, terminate the Tranche Notice and decline to sell any Tranche Shares on the Tranche

  

 13 








 
Closing Date; and (ii) the Investor may, at its option, decline to purchase any Tranche Shares on the Tranche Closing Date, and the unexercised portion (if any) of the Warrant that relates
to the terminated Tranche Notice shall thereafter no longer be exercisable under any circumstances. 
 2.4 Maximum
Placement. Investor shall not be obligated to purchase any additional Tranche Shares once the aggregate Tranche Purchase Price paid by Investor equals the Maximum Placement. 
 2.5 Share Sufficiency. On or before the date on which the Warrant becomes exercisable, the Company shall have a sufficient
number of duly authorized shares of Common Stock for issuance in such amount as may be required to fulfill its obligations pursuant to the Transaction Documents and any outstanding agreements with Investor and any Affiliate of Investor. 

ARTICLE 3 
 TERMINATION 
 3.1 Termination. The Investor may elect to terminate this Agreement and the
Company’s right to initiate subsequent Tranches to Investor under this Agreement (each, a “Termination”) upon the occurrence of any of the following: 
 (a) if, at any time, either the Company or any director or executive officer of the Company has engaged in a transaction or conduct
related to the Company that has resulted in (i) a SEC enforcement action, including without limitation such director or executive officer being sanctioned by the SEC, or (ii) a civil judgment or criminal conviction for fraud or
misrepresentation, or for any other offense that, if prosecuted criminally, would constitute a felony under applicable law; 
 (b) on any date after a Delisting Event that lasts for an aggregate of 20 Trading Days during any calendar year; 
 (c) if at any time the Company has filed for and/or is subject to any bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief under any bankruptcy law or any law for the relief of debtors
instituted by or against the Company or any Subsidiary of the Company; 
 (d) the Company is in material breach or
default of any Material Agreement, which breach or default could have a Material Adverse Effect; 
 (e) the Company is in
material breach or default of this Agreement, any Transaction Document, or any agreement with Investor or any Affiliate of Investor and such breach or default is not cured within 10 Trading Days after written notice of such breach or default;

 (f) upon the occurrence of a Fundamental Transaction; 
 (g) so long as any Preferred Shares are outstanding, the Company effects or publicly announces its intention to create a security
senior to the Series A Preferred Stock or substantially altering the capital structure of the Company in a manner that materially adversely affects the rights or preferences of the Series A Preferred Stock; and 
  

 14 








 (h) on the Termination Date. 
 3.2 Company Termination. The Company may at any time in its sole discretion terminate (a “Company
Termination”) this Agreement and its right to initiate future Tranches by providing 30 days advanced written notice (“Termination Notice”) to Investor. 
 3.3 Effect of Termination. Except as otherwise provided herein, the termination of this Agreement will have no effect on any
Common Shares, Preferred Shares, Warrant or DWAC Shares previously issued, delivered or credited, or on any then-existing rights of any holder thereof. Notwithstanding any other provision of this Agreement, the Commitment Fee (to the extent it has
become due under the terms of this Agreement as the result of the purchase of Tranche Shares by Investor) is payable despite any termination of this Agreement and all fees paid to Investor or its counsel are non-refundable. 
 ARTICLE 4 
 REPRESENTATIONS AND WARRANTIES 
 4.1 Representations and Warranties of the Company. Except
as set forth under the corresponding section of the Disclosure Schedules, which shall be deemed a part hereof and which shall not contain any material non-public information, the Company hereby represents and warrants to, and as applicable covenants
with, Investor as of each Closing: 
 (a) Subsidiaries. All of the direct and indirect subsidiaries of the Company
are set forth on Section 4.1(a) to the Disclosure Schedule. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary, and all of such directly or indirectly owned capital stock or
other equity interests are owned free and clear of any Liens. All the issued and outstanding shares of capital stock of each Subsidiary are duly authorized, validly issued, fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. 
 (b) Organization and Qualification. Each of the Company and each
Subsidiary is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, as applicable, with the requisite power and authority to own and use its
properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company and each Subsidiary is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been
instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 
  

 15 








 (c) Authorization; Enforcement. The Company has the requisite corporate power
and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder or thereunder. The execution and delivery of each of the Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby or thereby have been duly authorized by all necessary action on the part of the Company and no further consent or action is required by the Company other than the filing
of the Certificate of Designations. Each of the Transaction Documents has been, or upon delivery will be, duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law. Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective certificate or articles of incorporation, by-laws or other organizational or charter documents. 
 (d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company, the issuance and sale
of the Securities and the consummation by the Company of the other transactions contemplated thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or
(iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and
state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected, or (iv) conflict with or violate the terms of any agreement by which the Company or any Subsidiary is bound or to
which any property or asset of the Company or any Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. Neither the Company nor any Subsidiary is required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than the filing of the Certificate of Designations and required federal and state securities filings and such filings and approvals as are required to be made or obtained under the applicable Trading
Market rules in connection with the transactions contemplated hereby, each of which has been, or (if not yet required to be filed) shall be, timely filed. 
  

 16 








 (f) Issuance of the Securities. The Securities are duly authorized and, when
issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens. The Company has reserved from its duly authorized capital stock a number of
shares of Common Stock and Preferred Stock for issuance of the Securities at least equal to the number of Securities which could be issued pursuant to the terms of the Transaction Documents, based on the then current anticipated exercise prices of
the Warrant. 
 (g) Capitalization. The capitalization of the Company is as described in the Company’s most
recently filed periodic SEC Report. The Company has not issued any capital stock since such filing, other than as set forth in Section 4.1(g) of the Disclosure Schedule. No Person has any right of first refusal, preemptive right, right
of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities or as set forth in the SEC Reports, there are no outstanding options,
warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares
of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or securities convertible into or exercisable for shares of Common
Stock. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than Investor) and will not result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange, or reset price under such securities. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state
securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors of the
Company or others is required for the issuance and sale of the Securities. Except as set forth in the SEC Reports, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 
 (h) SEC Reports; Financial Statements. The Company has filed all required SEC Reports for the two years preceding the Effective Date (or such shorter period as the Company was required by law to file such SEC Reports) on a
timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the
requirements of the Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all
material respects with applicable accounting requirements and the rules

  

 17 








 
and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in
such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated
subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (i) Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as
specifically disclosed in the SEC Reports, (i) there has been no event, occurrence or development that has had, or that would reasonably be expected to result in, a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, and (B) liabilities not required to be reflected in the Company’s financial
statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to
existing Company equity incentive plans as disclosed in the SEC Reports. The Company does not have pending before the SEC any request for confidential treatment of information. 
 (j) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the
knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county,
local or foreign) (collectively, an “Action”), which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities, or (ii) would, if there were an
unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the knowledge of the Company any director or officer thereof, is or has been the subject of any Action
involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC
involving the Company or any current or former director or officer of the Company acting in their capacity as an officer or director of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company or any Subsidiary under the Exchange Act or the Act. 
 (k) Labor
Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. 
 (l) Compliance. Neither the Company nor any Subsidiary (i) is in default under or in violation of (and, to the
Company’s knowledge, no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company

  

 18 








 
or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or
any other similar agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or
governmental body, or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business except in each case
under clauses (i), (ii) or (iii) as would not have a Material Adverse Effect. 
 (m) Regulatory Permits.
The Company and each Subsidiary possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has
received any notice of proceedings relating to the revocation or modification of any Material Permit. 
 (n) Title to
Assets. The Company and each Subsidiary have good and marketable title in fee simple to all real property owned by them that is material to the business of the Company and each Subsidiary and good and marketable title in all personal property
owned by them that is material to the business of the Company and each Subsidiary, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not materially interfere with the use made
and proposed to be made of such property by the Company and each Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and each Subsidiary are held by them under valid, subsisting and enforceable leases of which the Company and each Subsidiary are in compliance. 
 (o) Patents and Trademarks. The Company and each Subsidiary have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names,
copyrights, licenses and other similar rights that are necessary or material for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have would have a Material Adverse Effect (collectively,
the “Intellectual Property Rights”). Neither the Company nor any Subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any
Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights of the Company or each Subsidiary. 
 (p) Insurance. The Company and each Subsidiary are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and each Subsidiary are engaged, including but not limited to directors and officers insurance coverage at least equal to the Maximum Placement.
To the best of Company’s knowledge, such insurance contracts and policies are accurate and complete. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
  

 19 








 (q) Transactions With Affiliates and Employees. Except as set forth in the SEC
Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than
(i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other employee benefits, including stock option agreements under any equity incentive
plan of the Company. 
 (r) Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance
with all provisions of the Sarbanes-Oxley Act of 2002, which are applicable to it as of the date of the Commitment Closing. The Company and each Subsidiary maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company has established “disclosure controls and procedures” (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such
disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the
Company’s most recently filed periodic report under the Exchange Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of
the date prior to the filing date of the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the Company’s disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the
Company’s internal accounting controls or its disclosure controls and procedures or, to the Company’s knowledge, in other factors that could materially affect the Company’s internal accounting controls or its disclosure controls and
procedures. 
 (s) Certain Fees. Except for the payment of the Commitment Fee, no brokerage or finder’s fees
or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement. Investor shall
have no obligation with respect to any fees or with respect to any claims made by or on behalf of other

  

 20 








 
Persons for fees of a type contemplated in this Section 4.1(s) that may be due in connection with the transactions contemplated by this Agreement or the other Transaction Documents as
a result of any agreements made or purported to be made by the Company. 
 (t) Private Placement. Assuming the
accuracy of Investor representations and warranties set forth in Section 4.2, no registration under the Act is required for the offer and sale of the Securities by the Company to Investor as contemplated hereby. The issuance and sale of
the Securities hereunder does not contravene the rules and regulations of any Trading Market. 
 (u) Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act. 
 (v) Registration Rights. No Person (other than Investor pursuant to the Transaction Documents) has any right to cause the Company to effect the registration under the Act of any securities of the Company. 
 (w) Listing and Maintenance Requirements. The Common Stock is not registered pursuant to Section 12 of the Exchange Act.
The Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock nor has the Company received any notification that the SEC is contemplating terminating such
registration. The Company has not, in the 12 months preceding the Effective Date, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. 
 (x) Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti takeover provision under the Company’s Certificate of Incorporation (or
similar charter documents) or the laws of its state of incorporation that is or could become applicable to Investor as a result of Investor and the Company fulfilling their obligations or exercising their rights under the Transaction Documents,
including without limitation the Company’s issuance of the Securities and Investor’s ownership of the Securities. 
 (y) Disclosure. Except with respect to the information that will be, and to the extent that it actually is timely publicly disclosed by the Company pursuant to Section 2.2(b)(i)E, and notwithstanding any other
provision in this Agreement or the other Transaction Documents, neither the Company nor any other Person acting on its behalf has provided Investor or its agents or counsel with any information that constitutes or might constitute material,
non-public information, including without limitation this Agreement and the Exhibits, Appendices and Schedules hereto, unless prior thereto Investor shall have executed a written agreement regarding the confidentiality and use of such information.
The Company understands and confirms that

  

 21 








 
neither Investor nor any Affiliate of Investor shall have any duty of trust or confidence that is owed directly, indirectly, or derivatively to the Company or the shareholders of the Company or
to any other Person who is the source of material non-public information regarding the Company. No information contained in the Disclosure Schedules constitutes material non-public information. There is no adverse material information regarding the
Company as of the Effective Date that has not been publicly disclosed prior to the Effective Date. The Company understands and confirms that Investor will rely on the foregoing representations and covenants in effecting transactions in securities of
the Company. All disclosure provided to Investor regarding the Company, its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, furnished by or on behalf of the Company with respect to the
representations and warranties made herein are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading. 
 (z) No Integrated Offering. Neither the
Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of
the Securities to be integrated with prior offerings by the Company for purposes of the Act or which could violate any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Trading Market.

 (aa) Financial Condition. Based on the financial condition of the Company as of the date of the Commitment
Closing: (i) the fair saleable market value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as
they mature; (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the
particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the Company would receive,
were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company does not intend to incur
debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances, which lead it to believe that it
will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the date of the Commitment Closing. The SEC Reports set forth as of the dates thereof all outstanding secured and
unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness. 
 (bb) Tax Status. The Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all
other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of
all unpaid and unreported taxes) and has paid all taxes and other governmental assessments

  

 22 








 
and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books
provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, statue or local
tax. None of the Company’s tax returns is presently being audited by any taxing authority. 
 (cc) No General
Solicitation or Advertising. Neither the Company nor, to the knowledge of the Company, any of its directors or officers (i) has conducted or will conduct any general solicitation (as that term is used in Rule 502(c) of Regulation D) or
general advertising with respect to the sale of the Securities, or (ii) made any offers or sales of any security or solicited any offers to buy any security under any circumstances that would require registration of the Securities under the Act
or made any “directed selling efforts” as defined in Rule 902 of Regulation S. 
 (dd) Foreign Corrupt
Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any corrupt funds for unlawful contributions, gifts, entertainment or other
unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the
Foreign Corrupt Practices Act of 1977, as amended. 
 (ee) Acknowledgment Regarding Investor’s Purchase of
Securities. The Company acknowledges and agrees that Investor is acting solely in the capacity of arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that Investor
is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by Investor or any of its representatives or agents in
connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to Investor’s purchase of the Securities. The Company further represents to Investor that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives. 
 (ff) Accountants. The Company’s accountants are set forth in the SEC Reports and such accountants are an independent registered public accounting firm as required by the Act. 
 (gg) No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably
anticipated by the Company to arise, between the accountants and lawyers formerly or presently employed by the Company, and the Company is current with respect to any fees owed to its accountants and lawyers, except as in the normal course of
business. 
  

 23 








 (hh) Registration Statements and Prospectuses. 
 (i) The offer and sale of the Common Shares as contemplated hereby complies with the requirements of Rule 415 under the Act.

 (ii) The Company has not, directly or indirectly, used or referred to any “free writing prospectus” (as
defined in Rule 405 under the Act) except in compliance with Rules 164 and 433 under the Act. 
 (ii) Section 5
Compliance. No representation or warranty or other statement made by Company in the Transaction Documents contains any untrue statement or omits to state a material fact necessary to make any of them, in light of the circumstances in which it
was made, not misleading. The Company is not aware of any facts or circumstances that would cause the transactions contemplated by the Transaction Documents, when consummated, to violate Section 5 of the Act or other federal or state securities
laws or regulations. 
 4.2 Representations and Warranties of Investor. Investor hereby represents and warrants as
of the Effective Date as follows: 
 (a) Organization; Authority. Investor is an entity duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization with full right, company power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out
its obligations thereunder. The execution, delivery and performance by Investor of the transactions contemplated by this Agreement have been duly authorized by all necessary company or similar action on the part of Investor. Each Transaction
Document to which it is a party has been (or will be) duly executed by Investor, and when delivered by Investor in accordance with the terms hereof, will constitute the valid and legally binding obligation of Investor, enforceable against it in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (b) Investor Status. At the time Investor was offered the Securities, it was, and at the Effective Date it is an
“accredited investor” as defined in Rule 501(a) under the Act. 
 (c) Experience of Investor. Investor,
either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so
evaluated the merits and risks of such investment. Investor is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 
  

 24 








 (d) General Solicitation. Investor is not purchasing the Securities as a
result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or
general advertisement. 
 The Company acknowledges and agrees that Investor does not make or has not made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Section 4.2. 
 ARTICLE 5 
 OTHER AGREEMENTS OF THE PARTIES 
 5.1 Transfer Restrictions 
 (a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than (i) pursuant to an effective
Registration Statement or Rule 144, (ii) to the Company, (iii) to an Affiliate of Investor, or (iv) in connection with a pledge as contemplated in Section 5.1(b), the Company may require the transferor thereof to provide
to the Company an opinion of Luce Forward Hamilton & Scripps LLP (“Luce Forward”), or other counsel selected by the transferor and reasonably acceptable to the Company, to the effect that such transfer does not require
registration of such transferred Securities under the Act. 
 (b) Investor agrees to the imprinting, so long as is
required by this Section 5.1, of the following legend, or substantially similar legend, on any certificate evidencing Securities other than DWAC Shares: 
 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO
THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN SECURED BY SUCH SECURITIES. 
  

 25 








 The Company agrees to cause such legend to be removed immediately upon effectiveness of a Registration
Statement, subject to receipt of customary undertakings regarding Investor’s compliance in connection with any sale of the Securities with (i) the manner of sale provisions set forth in the Prospectus and (ii) the prospectus delivery
requirements of the Act, or when any Common Shares are eligible for sale under Rule 144. Company further acknowledges and agrees that Investor may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or
grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Act and who agrees to be bound by the provisions of this Agreement and, if required
under the terms of such arrangement, Investor may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At Investor’s reasonable expense, the Company will execute and deliver such documentation as a pledgee or secured
party of Securities may reasonably request in connection with a pledge or transfer of the Securities. 
 5.2 Furnishing of
Information. As long as Investor owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the Effective
Date pursuant to the Exchange Act. Upon the request of Investor, the Company shall deliver to Investor a written certification of a duly authorized officer as to whether it has complied with the preceding sentence. As long as Investor owns
Securities, if the Company is not required to file reports pursuant to such laws, it will prepare and furnish to Investor and make publicly available in accordance with Rule 144(c) such information as is required for Investor to sell the Securities
under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may reasonably request, all to the extent required from time to time to enable such Person to sell such Securities without registration
under the Act within the limitation of the exemptions provided by Rule 144. 
 5.3 Integration. The Company shall
not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Act) that would be integrated with the offer or sale of the Securities in a manner that would require the
registration under the Act of the sale of the Securities to Investor or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval
prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 
 5.4 Securities Laws Disclosure; Publicity. The Company shall timely file a Current Report on Form 8-K, and in the Company’s discretion file a press release, in each case reasonably
acceptable to Investor, disclosing the material terms of the transactions contemplated hereby. The Company and Investor shall consult with each other in issuing any press releases with respect to the transactions contemplated hereby, and neither the
Company nor Investor shall issue any such press release or otherwise make any such public statement without the prior consent of the Company, with respect to any such press release of Investor, or without the prior consent of Investor, with respect
to any such press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law or Trading Market regulations, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of Investor, or include the name of Investor in any 
  

 26 








 
filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of Investor, except (i) as contained in the Current Report on Form 8-K and press release
described above, (ii) as required by federal securities law in connection with any registration statement under which the Common Shares are registered, or (iii) to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide Investor with prior notice of such disclosure, or (iv) to the extent such disclosure is required in any Form 8-K, Form 10-Q or Form 10-K report filed by the Company. 
 5.5 Shareholders Rights Plan. No claim will be made or enforced by the Company or, to the knowledge of the Company, any other
Person that Investor is an “Acquiring Person” under any shareholders rights plan or similar plan or arrangement in effect or hereafter adopted by the Company, or that Investor could be deemed to trigger the provisions of any such plan or
arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and Investor. The Company shall conduct its business in a manner so that it will not become subject to the Investment
Company Act of 1940, as amended. 
  

 27 








 5.6 Non-Public Information. The Company covenants and agrees that neither it
nor any other Person acting on its behalf will provide Investor or its agents or counsel with any information that the Company believes or reasonably should believe constitutes material non-public information, unless prior thereto Investor shall
have executed a written agreement regarding the confidentiality and use of such information. On and after the Effective Date, neither Investor nor any Affiliate Investor shall have any duty of trust or confidence that is owed directly, indirectly,
or derivatively, to the Company or the shareholders of the Company, or to any other Person who is the source of material non-public information regarding the Company. The Company understands and confirms that Investor shall be relying on the
foregoing in effecting transactions in securities of the Company. 
 5.7 Reimbursement. If Investor becomes
involved in any capacity in any proceeding by or against any Person who is a stockholder of the Company (except as a result of sales, pledges, margin sales and similar transactions by Investor to or with any current stockholder), solely as a result
of Investor’s acquisition of the Securities under this Agreement, the Company will reimburse Investor for its reasonable legal and other expenses (including the cost of any investigation preparation and travel in connection therewith) incurred
in connection therewith, as such expenses are incurred, or will assume the defense of Investor in such matter. The reimbursement obligations of the Company under this Section 5.7 shall be in addition to any liability which the Company may
otherwise have, shall extend upon the same terms and conditions to any Affiliates of Investor who are actually named in such action, proceeding or investigation, and partners, directors, agents, employees and controlling persons (if any), as the
case may be, of Investor and any such Affiliate, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, Investor and any such Affiliate and any such Person. The Company also
agrees that neither Investor nor any such Affiliates, partners, directors, agents, employees or controlling persons shall have any liability to the Company or any Person asserting claims on behalf of or in right of the Company solely as a result of
acquiring the Securities under this Agreement, except in the case of a breach of this Agreement or any of the Transaction Documents by Investor or its Affiliates, partners, directors, agents, employees or controlling persons. 
 5.8 Indemnification 
 (a) Company Indemnification Obligation. Subject to the provisions of this Section 5.8, the Company will indemnify and hold Investor and any Warrant holder, their Affiliates and
attorneys, and each of their directors, officers, shareholders, partners, employees, agents, and any person who controls Investor within the meaning of Section 15 of the Act or Section 20 of the Exchange Act (collectively, the
“Investor Parties” and each an “Investor Party”), harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys’ fees and costs of investigation (collectively, “Losses”) that any Investor Party may suffer or incur as a result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (b) any action instituted against any Investor Party, or any of them or their respective Affiliates, by any stockholder of the
Company who is not an Affiliate of an Investor Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of Investor’s representations, warranties 
  

 28 








 
or covenants under the Transaction Documents or any agreements or understandings Investor may have with any such stockholder or any violations by Investor of state or federal securities laws or
any conduct by Investor which constitutes fraud, gross negligence, willful misconduct or malfeasance), (c) any untrue statement or alleged untrue statement of a material fact contained in a Registration Statement (or in a Registration Statement
as amended by any post-effective amendment thereof by the Company) or arising out of or based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
and/or (d) any untrue statement or alleged untrue statement of a material fact included in any Prospectus ( or any amendments or supplements to any Prospectus), in any free writing prospectus, in any “issuer information” (as defined
in Rule 433 under the Act) of the Company, or in any Prospectus together with any combination of one or more of the free writing prospectuses, if any, or arising out of or based upon any omission or alleged omission to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 (b) Indemnification Procedures. If any action shall be brought against an Investor Party in respect of which indemnity may be sought pursuant to this Agreement, such Investor Party shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing. The Investor Parties shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and
expenses of such counsel shall be at the expense of the Investor Parties except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period
of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict with respect to the dispute in question on any material issue between the position of
the Company and the position of the Investor Parties such that it would be inappropriate for one counsel to represent the Company and the Investor Parties. The Company will not be liable to the Investor Parties under this Agreement for any
settlement by an Investor Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed. 
 5.9 Reservation of Securities. The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents in such amount as may
be required to fulfill its obligations in full under the Transaction Documents. 
 5.10 Prospectus Availability and
Changes. The Company will make available to Investor upon request, and thereafter from time to time will furnish Investor, as many copies of any Prospectus (or of the Prospectus as amended or supplemented if the Company shall have made any
amendments or supplements thereto after the effective date of the applicable Registration Statement) as Investor may request for the purposes contemplated by the Act; and in case Investor is required to deliver a prospectus after the nine-month
period referred to in Section 10(a)(3) of the Act in connection with the sale of the Common Shares, or after the time a post-effective amendment to the applicable Registration Statement is required pursuant to Item 512(a) of Regulation S-K
under the Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of
the Act or Item 512(a) of Regulation S-K under the Act, as the case may be. Investor agrees that, upon written notice from the Company that such amendment or supplement is pending and prior to its receipt of such amendment or supplement to the
Prospectus, Investor shall not sell any Common Shares under the Registration Statement. 
  

 29 








 The Company will advise Investor promptly of the happening of any event within the time
during which a Prospectus is required to be delivered under the Act which could require the making of any change in the Prospectus then being used so that the Prospectus would not include an untrue statement of material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, and to advise Investor promptly if, during such period, it shall become necessary to amend or supplement
any Prospectus to cause such Prospectus to comply with the requirements of the Act, and in each case, during such time, to prepare and furnish, at the Company’s expense, to Investor promptly such amendments or supplements to such Prospectus as
may be necessary to reflect any such change or to effect such compliance. Investor agrees that, upon written notice from the Company that such amendment or supplement is pending and prior to its receipt of such amendment or supplement to the
Prospectus, Investor shall not sell any Common Shares under the Registration Statement. 
 5.11 Required Approval.
No transactions contemplated under this Agreement or the Transaction Documents shall be consummated for an amount that would require approval by any Trading Market or Company stockholders under any approval provisions, rules or regulations of any
Trading Market applicable to the Company, unless and until such approval is obtained. Company shall use best efforts to obtain any required approval as soon as possible. 
 5.12 Activity Restrictions. For so long as Investor or any of its Affiliates holds any Preferred Shares, Warrant or Warrant Shares, neither Investor nor any Affiliate will: (i) vote any
shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or influence any Person with respect to any voting securities of the Company; (ii) engage or participate in any actions, plans or proposals which relate to
or would result in (a) acquiring additional securities of the Company, alone or together with any other Person, which would result in beneficially owning or controlling more than 9.99% of the total outstanding Common Stock or other voting
securities of the Company, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Company or any of its subsidiaries, (c) a sale or transfer of a material amount of assets of the Company or
any of its subsidiaries, (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any
material change in the present capitalization or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, including but not limited to, if the Company is a registered closed-end
investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940, (g) changes in the Company’s charter, bylaws or instruments
corresponding thereto or other actions which may impede the acquisition of control of the Company by any Person, (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to
be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act, or
(j) any action, intention, plan or arrangement similar to any of those enumerated above; or (iii) request the Company or its directors, officers, employees, agents or representatives to amend or waive any provision of this
Section 5.12. 
  

 30 








 5.13 Registration Statements and Prospectuses. 
 (a) Company will use its best efforts to file within 30 calendar days after the Effective Date (or as soon as possible thereafter), to
cause to become effective as soon as possible thereafter, and to remain effective until all Common Shares have been sold or are Rule 144 Eligible, a Registration Statement for the resale of all Common Shares issued or issuable hereunder (including
without limitation all Warrant Shares underlying the Warrant and any Common Shares that may be issued to the Investor in payment of the Commitment Fee). Each Registration Statement shall comply when it becomes effective, and, as amended or
supplemented, at the time of any Tranche Notice Date, Tranche Closing Date, or issuance of any Common Shares, and at all times during which a prospectus is required by the Act to be delivered in connection with any sale of Common Shares, will
comply, in all material respects, with the requirements of the Act. 
 (b) Each Registration Statement, as of its
respective effective time, will not, as applicable, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 
 (c) Each Prospectus will comply, as of its date and the date it will be filed with the SEC, and, at the time of any Tranche Notice
Date, Tranche Closing Date, or issuance of any Common Shares, and at all times during which a prospectus is required by the Act to be delivered in connection with any sale of Common Shares, will comply, in all material respects, with the
requirements of the Act. 
 (d) At no time during the period that begins on the date a Prospectus is filed with the SEC
and ends at the time a Prospectus is no longer required by the Act to be delivered in connection with any sale of Common Shares will any such Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 (e) Each Registration Statement will meet, and the offering and sale of the Common Shares as contemplated hereby will comply with, the requirements of Rule 415 under the Act. 
 (f) The Company will not, directly or indirectly, use or refer to any “free writing prospectus” (as defined in Rule 405
under the Act) except in compliance with Rules 164 and 433 under the Act. 
  

 31 








 5.14 Investor Due Diligence. Investor shall have the right and opportunity at
its own expense to conduct due diligence with respect to any Registration Statement or Prospectus in which the name of Investor or any Affiliate of Investor appears. 
 ARTICLE 6 
 MISCELLANEOUS 
 6.1 Fees and Expenses. Except for the $20,000.00 non-refundable document preparation fee previously paid by the Company to
counsel for Investor (which shall cover initial drafts of the Transaction Documents and one week of legal services), the receipt of which is hereby acknowledged, and the $5,000.00 non-refundable administrative fee payable to counsel for Investor at
each Tranche Closing, or as may be otherwise provided in this Agreement, each party shall pay the fees and expenses of its own advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of the Transaction Documents. The Company acknowledges and agrees that Luce Forward solely represents Investor, and does not represent the Company or its interests in connection with the
Transaction Documents or the transactions contemplated thereby. The Company shall pay all stamp and other taxes and duties levied in connection with the sale of the Securities, if any, and, except as otherwise specifically provided herein, Investor
shall pay all commissions, discounts, legal fees and other expenses that Investor incurs in connection with the sale of the Securities. 
 6.2 Notices. Unless a different time of day or method of delivery is set forth in the Transaction Documents, any and all notices or other communications or deliveries required or permitted
to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or electronic mail prior to 5:30 p.m. Eastern time
on a Trading Day and an electronic confirmation of delivery is received by the sender, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered later than 5:30 p.m. Eastern time or on a day that is
not a Trading Day, (c) three Trading Days following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The addresses
for such notices and communications are those set forth following the signature page hereof, or such other address as may be designated in writing hereafter, in the same manner, by such Person. 
 6.3 Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the
case of an amendment, by the Company and Investor or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any
manner impair the exercise of any such right. 
 6.4 Headings. The headings herein are for convenience only, do
not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 
  

 32 








 6.5 Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Investor, which consent shall not be unreasonably withheld
or delayed. Investor may assign any or all of its rights under this Agreement (a) to any Affiliate, or (b) to any Person to whom Investor assigns or transfers any Securities. 
 6.6 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 5.8. 
 6.7 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the laws of the State of New York, without regard to the principles of conflicts of law that would require or permit the application of the laws of any other jurisdiction.
Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions
of the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses reasonably incurred in connection with the
investigation, preparation and prosecution of such action or proceeding. 
 6.8 Survival. The representations and
warranties contained herein shall survive the Closing and the delivery and exercise of the Securities. 
 6.9
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof. 
  

 33 








 6.10 Severability. If any provision of this Agreement is held to be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision
that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 
 6.11 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if
requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities. 
 6.12 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of Investor and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 
 6.13 Payment Set Aside. To the extent that the Company makes a payment or payments to Investor pursuant to any Transaction
Document or Investor enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or
equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred. 
 6.14 Liquidated Damages. The Company’s obligations to pay any
partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact
that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been cancelled. 
 6.15 Time of the Essence. Time is of the essence with respect to all provisions of this Agreement that specify a time for performance. 
  

 34 








 6.16 Construction. The parties agree that each of them and/or their respective
counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the
interpretation of the Transaction Documents or any amendments hereto. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied
against any party. 
 6.17 Entire Agreement. This Agreement, together with the Exhibits, Appendices and Schedules
hereto, contains the entire agreement and understanding of the parties, and supersedes all prior and contemporaneous agreements, term sheets, letters, discussions, communications and understandings, both oral and written, which the parties
acknowledge have been merged into this Agreement. No party, representative, attorney or agent has relied upon any collateral contract, agreement, assurance, promise, understanding or representation not expressly set forth hereinabove. The parties
hereby expressly waive all rights and remedies, at law and in equity, directly or indirectly arising out of or relating to, or which may arise as a result of, any Person’s reliance on any such assurance. 
  

 35 








 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by
their respective authorized signatories as of the date first indicated above. 
  

			
	 IMMUNOCELLULAR THERAPEUTICS, LTD.

		
	By:	 	 /s/ Manish Singh.

	Name:	 	Manish Singh, Ph.D.
	Title:	 	President and Chief Executive Officer
	
	SOCIUS LIFE SCIENCES CAPITAL GROUP, LLC
		
	By:	 	 /s/ Terry Peizer

	Name:	 	Terry Peizer
	Title:	 	Managing Director


  







 Addresses for Notice 
  

			
	 To Company:
  
 ImmunoCellular Therapeutics, Ltd.
 21900 Burbank
Boulevard, 3rd Floor
 Woodland Hills, California 91367
 Attn: Manish Singh, Ph.D.
 Fax No.: (818) 992-2901
 Email: manish.singh@imuc.com
  
 with a copy to:
  
 TroyGould PC
 1801 Century Park East, Suite 1600
 Los Angeles, California 90067-2367
 Attn: Sanford J.
Hillsberg, Esq.
 Fax No.: (310) 201-4746
 Email: SHillsberg@troygould.com
	 	
		
		 	 To Investor:
  
 Socius Life Sciences Capital Group, LLC
 11150 Santa
Monica Boulevard, Suite 1500
 Los Angeles, California 90025
 Fax No.: (310) 444-5300
 Email: info@sociuscg.com

		
		 	 with a copy to:
  
 Luce Forward Hamilton & Scripps LLP
 601 South
Figueroa Street, Suite 3900
 Los Angeles, California 90017
 Attention: John C. Kirkland, Esq.
 Fax No.: (213) 452-8035
 Email: jkirkland@luce.com









 Exhibit A 
 Form of Warrant 







 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO
WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF
(A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT
REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED
BY THE SECURITIES. 
 IMMUNOCELLULAR THERAPEUTICS, LTD. 

 WARRANT TO PURCHASE COMMON STOCK 

 

			
	 Warrant No.: 2009-1
	 	Issuance Date: December 3, 2009

 Number of Warrant Shares: 27,000,000 
 Initial Exercise Price: $[        ] per share 
 ImmunoCellular Therapeutics, Ltd., a Delaware corporation (“Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, [                    ], the holder hereof or its designees or assigns (“Holder”), is entitled, subject to the
terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock (including any Warrant to Purchase Common Stock issued in exchange, transfer or
replacement hereof, the “Warrant”), at any time or times after issuance and until 11:59 p.m. Eastern time on the fifth anniversary of the Tranche Notice Date applicable to that Warrant Tranche (as defined below), subject to
acceleration pursuant to Section 3.3 hereof, that number of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock set forth above and as adjusted herein (the “Warrant Shares”). This
Warrant may only be exercised from time to time for an Aggregate Exercise Price (as defined below) equal to 135% of the cumulative amount of Tranche Purchase Prices under Tranche Notices delivered prior to the date of exercise. Except as otherwise
defined herein, capitalized terms in this Warrant shall have the meanings set forth in ARTICLE 13 hereof. 
  

 1 








 This Warrant shall consist of tranches (the “Warrant Tranches”), with a separate
tranche being created upon each delivery of a Tranche Notice. Each Warrant Tranche will cover the exercise for a five-year period commencing on the Tranche Notice Date for the applicable Tranche Notice of a number of shares of Common Stock that will
have an Aggregate Exercise Price (as defined below) equal to 135% of the Tranche Purchase Price for that Tranche Notice. This Warrant shall include a schedule (the “Warrant Tranche Schedule”) that sets forth the issuance date, number of
Warrant Shares and Exercise Price for each Warrant Tranche. No portion of this Warrant shall vest or be exercisable except under the Warrant Tranches. 
 ARTICLE 1 
 EXERCISE OF WARRANT. 
 1.1 Mechanics of Exercise. 
 1.1.1 Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder on any day on or after the Issuance Date, in whole or in part, by (i) delivery of a written notice
to the Company, in the form attached hereto as Appendix 1 (the “Exercise Notice”), of the Holder’s election to exercise this Warrant, and (ii) payment to the Company of an amount equal to the applicable Exercise
Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”), with such payment made, at Investor’s option, (x) in cash or by wire transfer of immediately
available funds, (y) by the issuance and delivery of a recourse promissory note substantially in the form attached hereto as Appendix 2 (each, a “Recourse Note”), or (z) if applicable, by cashless exercise pursuant
to Section 1.3. 
 1.1.2 The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to
purchase the remaining number of Warrant Shares. 
 1.1.3 On the Trading Day on which the Company has received each of
the Exercise Notice and the Aggregate Exercise Price (the “Exercise Delivery Documents”) from the Holder by 6:30 p.m. Eastern time, or on the next Trading Day if the Exercise Delivery Documents are received after 6:30 p.m. Eastern
time or on a non-Trading Day (in each case, the “Exercise Delivery Date”), the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the Holder and an electronic copy
of its share issuance instructions to the Holder and to the Company’s transfer agent (the “Transfer Agent”), with such electronic transmissions to comply with the notice provisions contained in Section 6.2 of the
Purchase Agreement, and shall instruct and authorize the Transfer Agent to credit such aggregate number of freely-tradable Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance
account with The Depository Trust Company (DTC) through the Fast Automated Securities Transfer (FAST) Program through its Deposit Withdrawal Agent Commission (DWAC) system, with such credit to occur no later than 5:30 p.m. Eastern Time on the
Trading Day following the Exercise

  

 2 








 
Delivery Date, time being of the essence. If the Warrant Shares are not timely credited as DWAC Shares by 12:00 p.m. Eastern Time on the Trading Day following the Exercise Delivery Date (and
including the circumstance where the Warrant Shares are credited as DWAC Shares by 5:30 p.m. Eastern Time on such Trading Day), then the Tranche Closing Date applicable to the Exercise Notice shall be extended by one Trading Day for each Trading Day
that credit of DWAC Shares is not made by 12:00 p.m. 
 1.1.4 Upon delivery of the Exercise Delivery Documents, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC
account. Any Warrant delivered in connection with a Tranche Notice and exercised by Holder shall be deemed exercised (i) on the Tranche Notice Date, if exercised by 6:30 p.m. Eastern time on the Tranche Notice Date, or (ii) on the next
Trading Day, to the extent exercised by Investor after 6:30 p.m. Eastern Time on the Tranche Notice Date or on any other date, in each case with Holder deemed to be a holder of record as of such date. 
 1.1.5 If this Warrant is submitted in connection with any exercise pursuant to this Section 1.1 and the number of Warrant
Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than one Trading Day after any exercise, and
at its own expense and its option, either (i) issue a new Warrant (in accordance with Section 6.4) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
less the number of Warrant Shares with respect to which this Warrant is exercised or (ii) make a suitable notation in the Warrant Tranche Schedule reflecting the revised number of Warrant Shares for which this Warrant is exercisable. No
fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all taxes which may be
payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. 
 1.2 Adjustments to
Exercise Price and Number of Shares. In addition to other adjustments specified herein, the Exercise Price of this Warrant and the number of shares of Common Stock issuable upon exercise of this Warrant shall be adjusted as follows:

 1.2.1 Exercise Price. The “Exercise Price” per share of Common Stock underlying this Warrant,
subject to further adjustment as provided herein, shall be as follows: (i) until the first Tranche Notice Date, the amount per Warrant Share set forth on the face of this Warrant, which is equal to Closing Bid Price for the Common Stock on the
Trading Day prior to the Effective Date, and (ii) with respect to the portion of this Warrant that becomes exercisable on any Tranche Notice Date (including the first Tranche Notice Date), an amount per Warrant Share equal to the Closing Bid
Price of a share of Common Stock on such Tranche Notice Date. 
  

 3 








 1.2.2 Number of Shares. The number of Warrant Shares underlying each Warrant
Tranche, subject to further adjustment as provided herein, shall be equal to the Tranche Purchase Price set forth in the Tranche Notice relating to that Warrant Tranche multiplied by 135%, with the resulting sum divided by the Closing Bid Price of a
share of Common Stock on the Tranche Notice Date. For example, if the Tranche Purchase Price is $1,000,000 and the Closing Bid Price is $0.50, then the number of Warrant Shares underlying that Warrant Tranche shall be $1,000,000 x 135% = $1,350,000
divided by $0.50 – 2,700,000 shares of Common Stock. On each Tranche Notice Date, the number of Warrant Shares underlying the related Warrant Tranche shall vest and become exercisable, and the aggregate number of Warrant Shares underlying this
Warrant that are currently exercisable shall automatically adjust up or down to account for the change in the number of Warrant Shares covered by the new Warrant Tranche and for any Warrant Shares issued upon any prior or simultaneous exercise of
this Warrant. The total number of Warrant Shares that may be issued upon all exercises of this Warrant shall not exceed an aggregate of 27,000,000 shares (subject to adjustment as provided in ARTICLE 2). 
 1.3 Cashless Exercise. Notwithstanding anything contained herein to the contrary, if at any time there is not a current, valid
and effective registration statement covering the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant Shares”), the Holder may, in its sole discretion, exercise this Warrant in whole or in part and,
in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common
Stock determined according to the following formula (a “Cashless Exercise”): 
  

					
	Net Number =	 	(B-C) x A	 	
		 	B	 	

 For purposes of the foregoing formula: 
 A = the total number of shares with respect to which this Warrant is then being exercised. 
 B = the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg) for the five (5) consecutive
Trading Days ending on the date immediately preceding the date of the Exercise Notice. 
 C = the Exercise Price then in effect
for the applicable Warrant Shares at the time of such exercise. 
 1.4 Company’s Failure to Timely Deliver
Securities. If the Company shall fail for any reason or for no reason to credit to the Holder’s balance account with DTC, by 5:30 p.m. Eastern time on the Trading Day following the Exercise Delivery Date, the number of shares of Common
Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant, then, in addition to all other remedies available to the Holder, the Company shall pay in cash to the Holder on each day after such Trading Day that the issuance
of such shares of Common Stock is not timely effected an amount equal to 1.5% of the product of (A) the sum of the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is

  

 4 








 
entitled and (B) the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding the last possible date which the Company could have issued such shares of
Common Stock to the Holder without violating Section 1.1. In addition to the foregoing, if after the Company’s receipt of the facsimile copy of an Exercise Notice the Company shall fail to timely credit the Holder’s balance
account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise hereunder, and the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company, then the Company shall, within one Trading Day after the Holder’s request and in the
Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to credit such Holder’s balance account with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder and to issue such Warrant
Shares shall terminate, or (ii) promptly honor its obligation to credit such Holder’s balance account with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder and pay cash to the
Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock sold by Holder in satisfaction of its obligations, times (B) the Closing Bid Price on the date of exercise.

 1.5 Exercise Limitation. Notwithstanding any other provision, at no time may the Holder (a) exercise this
Warrant such that the number of Warrant Shares to be received pursuant to such exercise exceeds the lesser of 27,000,000 shares or 135.0% of the aggregate of all Tranche Purchase Prices under and in connection with all Tranche Notices delivered
pursuant to the Purchase Agreement prior to the date of exercise; or (b) exercise this Warrant such that the number of Warrant Shares to be received pursuant to such exercise, aggregated with all other shares of Common Stock then owned by the
Holder beneficially or deemed beneficially owned by the Holder, would result in the Holder owning more than 4.99% of all of such Common Stock as would be outstanding on the date of exercise, as determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. In addition, as of any date, the aggregate number of shares of Common Stock into which this Warrant is exercisable within 61 days, together with all other shares of Common Stock then
beneficially owned (as such term is defined in Rule 13(d) under the Exchange Act) by Holder and its affiliates, shall not exceed 9.99% of the total outstanding shares of Common Stock as of such date. 
 1.6 Activity Restrictions. For so long as Holder or any of its affiliates holds this Warrant or any Warrant Shares, neither
Holder nor any affiliate will: (i) vote any shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or influence any Person with respect to any voting securities of the Company; (ii) engage or participate
in any actions, plans or proposals which relate to or would result in (a) acquiring additional securities of the Company, alone or together with any other Person, which would result in beneficially owning or controlling more than 9.99% of the
total outstanding Common Stock or other voting securities of the Company, (b) an extraordinary corporate transaction, such as a merger,

  

 5 








 
reorganization or liquidation, involving Company or any of its subsidiaries, (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries, (d) any
change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the present
capitalization or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, including but not limited to, if the Company is a registered closed-end investment company, any plans or
proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940, (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other
actions which may impede the acquisition of control of the Company by any Person, (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer
quotation system of a registered national securities association, (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act, or (j) any action, intention,
plan or arrangement similar to any of those enumerated above; or (iii) request the Company or its directors, officers, employees, agents or representatives to amend or waive any provision of this Section 1.6. 
 1.7 Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12. 
 1.8 Insufficient Authorized Shares. If at any time while any of the Warrant remains outstanding the Company does not have a
sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of the Warrant at least a number of shares of Common Stock equal to 110% of the number of shares of Common Stock as
shall from time to time be necessary to effect the exercise of Warrant to the extent it is then exercisable (the “Required Reserve Amount”) (an “Authorized Share Failure”), then the Company shall immediately take
all action necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the Warrant to the extent it is then exercisable. Without limiting the
generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than 90 days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting
of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its
stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. 
  

 6 








 ARTICLE 2 
 ADJUSTMENT UPON SUBDIVISION OR COMBINATION OF COMMON STOCK 
 If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a
greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date
combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately
increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this ARTICLE 2 shall become effective at the close of business on the date the subdivision or combination becomes effective. 
 ARTICLE 3 
 PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS 
 3.1 Purchase Rights. In addition to any
adjustments pursuant to ARTICLE 2 above, if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of
shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights. 
 3.2 Fundamental Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor
Entity assumes in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3.2 pursuant to written agreements in form and substance satisfactory to the Required Holders and
approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each holder of this Warrant in exchange for such Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding
number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
satisfactory to the Required Holders. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and

  

 7 








 
shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Fundamental
Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or
other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other
purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance
with the provisions of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive
securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an
exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such
Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such
Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental Transaction; provided, however, that in the event the Fundamental Transaction involves the issuance of cash or freely tradable securities by
an issuer listed on the New York Stock Exchange or the Nasdaq Stock Market, then the ability to exercise this Warrant shall expire on the consummation of that Fundamental Transaction. Provision made pursuant to the preceding sentence shall be in a
form and substance reasonably satisfactory to the Required Holders. The provisions of this Section 3.2 shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to
any limitations on the exercise of this Warrant. 
 3.3 Notwithstanding Section 3.2, in the event of a
Fundamental Transaction other than one in which the Successor Entity is a Public Successor Entity that assumes this Warrant such that this Warrant shall be exercisable for the publicly traded common stock of such Public Successor Entity, at the
request of the Holder delivered before the 90th day after the effective date of such Fundamental Transaction, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Trading
Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the value of the remaining unexercised portion of this Warrant on the date of such consummation, which value shall be determined
by use of the Black Scholes Option Pricing Model using a volatility equal to the 100 day average historical price volatility prior to the date of the public announcement of such Fundamental Transaction. 
  

 8 








 ARTICLE 4 
 NONCIRCUMVENTION 
 The Company hereby covenants
and agrees that the Company will not, by amendment of its Certificate or Articles of Incorporation, Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect
the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as
any of this Warrant is outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of this Warrant to the extent then exercisable,
110% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of this Warrant to the extent then exercisable (without regard to any limitations on exercise). 
 ARTICLE 5 
 WARRANT HOLDER NOT DEEMED A STOCKHOLDER 
 Except as otherwise specifically provided herein, the Holder,
solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed
to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such
Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or
otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this ARTICLE 5, the Company shall provide the Holder with copies of the same notices and other
information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders. 
  

 9 








 ARTICLE 6 
 REISSUANCE OF WARRANT 
 6.1 Transfer of
Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with
Section 6.4), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is
being transferred, a new Warrant (in accordance with Section 6.4), to the Holder representing the right to purchase the number of Warrant Shares not being transferred. 
 6.2 Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 6.4), representing the right to purchase the Warrant Shares then underlying this Warrant. 
 6.3 Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Warrant or Warrants (in accordance with Section 6.4), representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will
represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrant for fractional shares of Common Stock shall be given. 
 6.4 Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being
issued pursuant to Section 6.1 or Section 6.3, the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance,
does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and
conditions as this Warrant. 
 ARTICLE 7 
 NOTICES 
 Whenever notice is required to be given under this
Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 6.2 of the Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this
Warrant, including in reasonable detail a description of such action and the reason therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the
Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen days prior to the date on which the Company closes its books or takes a record (A) with respect to any

  

 10 








 
dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property to holders of shares of Common Stock as such or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made
known to the public prior to or in conjunction with such notice being provided to the Holder. 
 ARTICLE 8

 AMENDMENT AND WAIVER 
 Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it,
only if the Company has obtained the written consent of the Required Holders; provided that except as set forth in this Warrant no such action may increase the exercise price of any Warrant or decrease the number of shares or class of stock
obtainable upon exercise of any Warrant without the written consent of the Holder. No such amendment shall be effective to the extent that it applies to less than all of the holders of this Warrant. 
 ARTICLE 9 
 GOVERNING LAW 
 This Warrant shall be governed by and construed and enforced in accordance with, and all
questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. 
 ARTICLE 10 
 CONSTRUCTION; HEADINGS 
 This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person as the
drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. 
 ARTICLE 11 
 DISPUTE RESOLUTION 
 In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
shall submit the disputed determinations or arithmetic calculations via facsimile within 2 Trading Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to
agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Trading Days of such disputed determination or arithmetic calculation being

  

 11 








 
submitted to the Holder, then the Company shall, within 2 Trading Days submit via facsimile (a) the disputed determination of the Exercise Price or arithmetic calculation to an independent,
reputable investment bank or independent registered public accounting firm selected by Holder subject to Company’s approval, which may not be unreasonably withheld or delayed, or (b) the disputed arithmetic calculation of the Warrant
Shares to the Company’s independent registered public accounting firm. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and
the Holder of the results no later than 3 Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon
all parties absent demonstrable error. 
 ARTICLE 12 
 REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF 
 The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the right of the Holder right to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations
hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be
entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. 
 ARTICLE 13 
 DEFINITIONS 
 For purposes of this Warrant, in addition to the terms defined elsewhere herein, the
following terms shall have the following meanings: 
 13.1 “Bloomberg” means Bloomberg Financial
Markets. 
 13.2 “Closing Bid Price” and “Closing Sale Price” means, for any security
as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Trading Market, as reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate
the closing bid price or the closing trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00 p.m., Eastern time, as reported by Bloomberg, or, if the Trading Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as
reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or,
if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the

  

 12 








 
average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National Quotation
Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such
date shall be the fair market value as mutually determined by the Company and Holder. If the Company and Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to ARTICLE 11. All
such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 
 13.3 “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.001 per share, and
(ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock. 
 13.4 “Common Stock Deemed Outstanding” means, at any given time, the number of shares of Common Stock actually outstanding at such time, plus the number of shares of Common Stock
deemed to be outstanding pursuant to Section 3.1 hereof regardless of whether the Options or Convertible Securities are actually exercisable at such time, but excluding any shares of Common Stock owned or held by or for the account of the
Company or issuable upon exercise of this Warrant. 
 13.5 “Convertible Securities” means any stock or
securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. 
 13.6 “DWAC Shares” means all Warrant Shares issued or issuable to Holder or any Affiliate, successor or assign of Holder pursuant to this Warrant, all of which shall be (a) issued in electronic form,
(b) freely tradable and without restriction on resale, and (c) timely credited by Company to the specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar
program hereafter adopted by DTC performing substantially the same function, in accordance with instructions issued to and countersigned by the Transfer Agent of the Company. 
 13.7 “Eligible Market” means the Trading Market, The New York Stock Exchange, Inc., The NASDAQ Global Select Market,
The NASDAQ Global Market, The NASDAQ Capital Market, the NYSE Amex or the OTC Bulletin Board, but does not include the Pink Sheets. 
 13.8 “Fundamental Transaction” has the meaning set forth in the Purchase Agreement. 
 13.9 “Maximum Placement” has the meaning set forth in the Purchase Agreement. 
  

 13 








 13.10 “Options” means any rights, warrants or options to subscribe
for or purchase shares of Common Stock or Convertible Securities. 
 13.11 “Parent Entity” of a Person
means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or
Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction. 
 13.12 “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency
thereof. 
 13.13 “Public Successor Entity” means a Successor Entity that is a publicly traded
corporation whose stock is quoted or listed for trading on an Eligible Market. 
 13.14 “Purchase
Agreement” means the Preferred Stock Purchase Agreement dated December 3, 2009, by and among the Company and the investor referred to therein. 
 13.15 “Required Holders” means the Holders of this Warrant representing at least a majority of shares of Common Stock underlying this Warrant then outstanding. 
 13.16 “Successor Entity” means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into. 
 13.17 “Trading Day” means any day on which the Common Stock is traded on an Eligible Market; provided that it shall
not include any day on which the Common Stock (a) is suspended from trading, or (b) is scheduled to trade on such exchange or market for less than 5 hours. 
 13.18 “Trading Market” means the OTC Bulletin Board, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE Amex, or the New York Stock
Exchange, whichever is at the time the principal trading exchange or market for the Common Stock, but does not include the Pink Sheets inter-dealer electronic quotation and trading system. 
 13.19 “Tranche Closing Date” has the meaning set forth in the Purchase Agreement. 
 13.20 “Tranche Notice” has the meaning set forth in the Purchase Agreement. 
 13.21 “Tranche Notice Date” has the meaning set forth in the Purchase Agreement. 
 13.22 “Tranche Purchase Price” has the meaning set forth in the Purchase Agreement. 
  

 14 








 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly
executed as of the Issuance Date set out above. 
  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	  

	Name:	 	  

	Title:	 	  










 APPENDIX 1 
 EXERCISE NOTICE 
 IMMUNOCELLULAR THERAPEUTICS, LTD.

 The undersigned hereby exercises the right to purchase
                     shares of Common Stock (“Warrant Shares”) of ImmunoCellular Therapeutics, Ltd., a Delaware corporation
(“Company”), evidenced by the attached Warrant to Purchase Common Stock (“Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. The Holder
intends that payment of the Exercise Price shall be made as: 
  

					
		 	        	 	Cash Exercise with respect to                      Warrant
Shares
			
		 	        	 	Cashless Exercise with respect to                      Warrant Shares

			
		 	        	 	Recourse Note Exercise with respect to                      Warrant
Shares
		
	Please issue	 	
			
		 	        	 	A certificate or certificates representing said shares of Common Stock in the name specified below
			
		 	        	 	Said shares in electronic form to the Deposit/Withdrawal at Custodian (DWAC) account with Depository Trust Company (DTC) specified below.

  

			
	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  









 ACKNOWLEDGMENT 
 The Company hereby acknowledges the foregoing Exercise Notice and hereby directs
[                    ] to issue the above indicated number of shares of Common Stock as specified above, in accordance with the Transfer Agent
Instructions dated December 3, 2009 from the Company, and acknowledged and agreed to by the transfer agent. 
  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	
	Name:	 	
	Title:	 	









 APPENDIX 2 
 FORM OF NOTE 







 SECURED PROMISSORY NOTE 
  

			
	$[        ]	 	Date: [            ], 20[    ]

 FOR VALUE RECEIVED,
[                    ] (“Borrower”) promises to pay to the order of ImmunoCellular Therapeutics, Ltd.
(“Lender”), at [                    ], or at such other place as Lender may from time to time designate in writing, the
principal sum of $[        ], with interest, as follows: 
 1.
Interest. The principal balance outstanding from time to time under this Secured Promissory Note (this “Note”), shall bear interest from and after the date hereof at the rate of 2.0% per year. Interest shall be
calculated on a simple interest basis and the number of days elapsed during the period for which interest is being calculated. Payments of interest will be due on each annual anniversary of the date of this Note; provided that Borrower will
not be in default hereunder for failure to make any annual interest payment when due (other than on the Maturity Date) and the amount of interest not paid when due shall be added to the principal balance of this Note and such amount will thereafter
accrue interest at the rate set forth above. 
 2. Payments. If not sooner paid, the entire unpaid principal
balance, interest thereon and any other charges due and payable under this Note shall be due and payable on the fourth anniversary of the date of this Note (“Maturity Date”); provided, however, that no payments on this
Note will be due or payable so long as either (a) Lender is in default under any preferred stock purchase agreement for Series A Preferred Stock with Borrower or any Warrant issued pursuant thereto, any loan agreement or other material
agreement entered into with Borrower, or (b) there are any shares of Series A Preferred Stock of Lender issued or outstanding (each, a “Non-Payment Event”). Upon the termination or cure of any Non-Payment Event, Borrower’s
obligation to pay amounts outstanding on this Note will immediately be reinstated. Borrower shall have the right to prepay all or any part of the principal balance of this Note at any time without penalty or premium. In the event that Lender redeems
all or a portion of any shares of Series A Preferred Stock then held by Borrower, the proceeds of any such redemption will be applied by Borrower to pay down the accrued interest and outstanding principal of this Note and Lender will be permitted to
offset the full amount of such proceeds against amounts outstanding under this Note. All payments on this Note shall be first applied to interest, then to reduce the outstanding principal balance hereof. 
 3. Full Recourse Note. THIS IS A FULL RECOURSE PROMISSORY NOTE. Accordingly, notwithstanding that Borrower’s obligations under
this Note are secured by the Collateral, in the event of a material default hereunder, Lender shall have full recourse to all the other assets of Borrower. Moreover, Lender shall not be required to proceed against or exhaust any Collateral, or to
pursue any Collateral in any particular order, before Lender pursues any other remedies against Borrower or against any of Borrower’s assets. 
 4. Security 
 a. Pledge. As security for the due and prompt payment
and performance of all payment obligations under this Note and any modifications, replacements and extensions hereof (collectively, “Secured Obligations”), Borrower hereby pledges and grants a security

  

 1 








 
interest to Lender in all of Borrower’s right, title, and interest in and to all of the following, now owned or hereafter acquired or arising (together the “Collateral”):

 i. Publicly listed shares of common stock, preferred stock, bonds, notes and/or debentures that are freely tradeable
(collectively, “Pledged Securities”) with a fair market value on the date hereof at least equal to the principal amount of this Note, based upon the trading price of such securities on the OTC Bulletin Board, NASDAQ Capital Market,
NASDAQ Global Market, NASDAQ Global Select Market, NYSE Amex, or New York Stock Exchange; 
 ii. all rights of Borrower with
respect to or arising out of the Pledged Securities, including voting rights, and all equity and debt securities and other property distributed or distributable with respect thereto as a result of merger, consolidation, dissolution, reorganization,
recapitalization, stock split, stock dividend, reclassification, exchange, redemption, or other change in capital structure; and 
 iii. all proceeds, replacements, substitutions, accessions and increases in any of the Collateral. 
 b. Replacement
Securities. So long as any Secured Obligations remain outstanding, in the event that Borrower sells or disposes of any Pledged Securities, Borrower shall promptly provide replacement securities of equal or greater value than the Pledged
Securities. 
 c. Rights With Respect to Distributions. So long as no default shall have occurred and be continuing under
this Note, Borrower shall be entitled to receive any and all dividends and distributions made with respect to the Pledged Securities and any other Collateral. However, upon the occurrence and during the continuance of any default, Lender shall have
the sole right (unless otherwise agreed by Lender) to receive and retain dividends and distributions and apply them to the outstanding balance of this Note or hold them as Collateral, at Lender’s election. 
 d. Voting Rights. So long as no default shall have occurred and be continuing under this Note, Borrower shall be entitled to exercise
all voting rights pertaining to the Pledged Securities and any other Collateral. However, upon the occurrence and during the continuance of any default, all rights of Borrower to exercise the voting rights that Borrower would otherwise be entitled
to exercise with respect to the Collateral shall cease and (unless otherwise agreed by Lender) all such rights shall thereupon become vested in Lender, which shall thereupon have the sole right to exercise such rights. 
 e. Financing Statement; Further Assurances. Borrower agrees, concurrently with executing this Note, that Lender may file a UCC-1
financing statement relating to the Collateral in favor of Lender, and any similar financing statements in any jurisdiction in which Lender reasonably determines such filing to be necessary. Borrower further agrees that at any time and from time to
time Borrower shall promptly execute and deliver all further instruments and documents that Lender may request in order to perfect and protect the security interest granted hereby, or to enable Lender to exercise and enforce its rights and remedies
with respect

  

 2 








 
to any Collateral following an event of default. In addition, following an event of default, Borrower shall deliver the Collateral, including original certificates or other instruments
representing the Pledged Securities, to Lender to hold as secured party, and Borrower shall, if requested by Lender, execute a securities account control agreement. 
 f. Powers of Lender. Borrower hereby appoints Lender as Borrower’s true and lawful attorney-in-fact to perform any and all of the following acts, which power is coupled with an interest, is
irrevocable until the Secured Obligations are paid and performed in full, and may be exercised from time to time by Lender in its discretion: To take any action and to execute any instrument which Lender may deem reasonably necessary or desirable to
accomplish the purposes of this Section 4(f) and, more broadly, this Note including, without limitation: (i) to exercise voting and consent rights with respect to Collateral in accordance with this Note, (ii) during the
continuance of any default hereunder, to receive, endorse and collect all instruments or other forms of payment made payable to Borrower representing any dividend, interest payment or other distribution in respect of the Collateral or any part
thereof and to give full discharge for the same, when and to the extent permitted by this Note, (iii) to perform or cause the performance of any obligation of Borrower hereunder in Borrower’s name or otherwise, (iv) during the
continuance of any default hereunder, to liquidate any Collateral pledged to Lender hereunder and to apply proceeds thereof to the payment of the Secured Obligations or to place such proceeds into a cash collateral account or to transfer the
Collateral into the name of Lender, all at Lender’s sole discretion, (v) to enter into any extension, reorganization or other agreement relating to or affecting the Collateral, and, in connection therewith, to deposit or surrender control
of the Collateral, (vi) to accept other property in exchange for the Collateral, (vii) to make any compromise or settlement Lender deems desirable or proper, and (viii) to execute on Borrower’s behalf and in Borrower’s name
any documents required in order to give Lender a continuing first lien upon the Collateral or any part thereof. 
 5.
Additional Terms 
 a. No Waiver. The acceptance by Lender of payment of a portion of any installment when
due or an entire installment but after it is due shall neither cure nor excuse the default caused by the failure of Borrower timely to pay the whole of such installment and shall not constitute a waiver of Lender’s right to require full payment
when due of any future or succeeding installments. 
 b. Default. Any one or more of the following shall constitute a
“default” under this Note: (i) a default in the payment when due of any amount hereunder, (ii) Borrower’s refusal to perform any material term, provision or covenant under this Note, (iii) the commencement of any
liquidation, receivership, bankruptcy, assignment for the benefit of creditors or other debtor-relief proceeding by or against Borrower, (iv) the transfer by Borrower of any Pledged Securities without being replaced by Pledged Securities in
accordance with Section 4(b), and (iv) the levying of any attachment, execution or other process against Borrower, the Collateral or any material portion thereof. 
  

 3 








 c. Default Rights 
 i. Upon the occurrence of any payment default Lender may, at its election, declare the entire balance of principal and interest under this
Note immediately due and payable. A delay by Lender in exercising any right of acceleration after a default shall not constitute a waiver of the default or the right of acceleration or any other right or remedy for such default. The failure by
Lender to exercise any right of acceleration as a result of a default shall not constitute a waiver of the right of acceleration or any other right or remedy with respect to any other default, whenever occurring. 
 ii. Further, upon the occurrence of any material non-monetary default, following 15 days notice from Lender to Borrower specifying the
default and demanded manner of cure for any non-monetary default, Lender shall thereupon and thereafter have any and all of the rights and remedies to which a secured party is entitled after a default under the applicable Uniform Commercial Code, as
then in effect. In addition to Lender’s other rights and remedies, Borrower agrees that, upon the occurrence of default, Lender may in its sole discretion do or cause to be done any one or more of the following: 
 (a) Proceed to realize upon the Collateral or any portion thereof as provided by law, and without liability for any diminution in price
which may have occurred, sell the Collateral or any part thereof, in such manner, whether at any public or private sale, and whether in one lot as an entirety, or in separate portions, and for such price and other terms and conditions as is
commercially reasonable given the nature of the Collateral. 
 (b) If notice to Borrower is required, give written notice to
Borrower at least ten days before the date of sale of the Collateral or any portion thereof. 
 (c) Transfer all or any part of
the Collateral into Lender’s name or in the name of its nominee or nominees. 
 (d) Vote all or any part of the Collateral
(whether or not transferred into the name of Lender ) and give all consents, waivers and ratifications in respect of the Collateral and otherwise act with respect thereto, as though Lender were the outright owner thereof. 
 iii. Borrower acknowledges that all or part of foreclosure of the Collateral may be restricted by state or federal securities laws, Lender
may be unable to effect a public sale of all or part of the Collateral, that a public sale is or may be impractical and inappropriate and that, in the event of such restrictions, Lender thus may be compelled to resort to one or more private sales to
a restricted group of purchasers who will be obliged to agree, among other things, to acquire the Collateral for their own account, for investment and not with a view to its distribution or resale. Borrower agrees that if reasonably necessary Lender
may resort to one or more sales to a single purchaser or a restricted or limited group of purchasers. Lender shall not be obligated to make any sale or other disposition, unless the terms thereof shall be satisfactory to it. 
  

 4 








 iv. If, in the opinion of Lender based upon written advice of counsel, any consent,
approval or authorization of any federal, state or other governmental agency or authority should be necessary to effectuate any sale or other disposition of any Collateral, Borrower shall execute all such applications and other instruments as may
reasonably be required in connection with securing any such consent, approval or authorization, and will otherwise use its commercially reasonable best efforts to secure the same. 
 v. The rights, privileges, powers and remedies of Lender shall be cumulative, and no single or partial exercise of any of them shall
preclude the further or other exercise of any of them. Any waiver, permit, consent or approval of any kind by Lender of any default hereunder, or any such waiver of any provisions or conditions hereof, must be in writing and shall be effective only
to the extent set forth in writing. Any proceeds of any disposition of the Collateral, or any part thereof, may be applied by Lender to the payment of expenses incurred by Lender in connection with the foregoing, and the balance of such proceeds
shall be applied by Lender toward the payment of the Secured Obligations. 
 d. No Oral Waivers or Modifications. No
provision of this Note may be waived or modified orally, but only in a writing signed by Lender and Borrower. 
 e. Attorney
Fees. The prevailing party in any action by Lender to collect any amounts due under this Note shall be entitled to recover its reasonable attorneys fees and costs. 
 f. Governing Law. This Note has been executed and delivered in, and is to be construed, enforced, and governed according to the internal laws of, the State of New York without regard to its
principles of conflict of laws that would require or permit the application of the laws of any other jurisdiction. 
 g.
Severability. Whenever possible, each provision of this Note shall be interpreted in such manner as to be effective and valid under applicable law. However, if any provision of this Note shall be held to be prohibited by or invalid under
applicable law, it shall be ineffective only to the extent of such prohibition or invalidity without invalidating the remainder of that provision or the other provisions of this Note. 
 h. Entire Agreement. This Note contains the entire understanding of the parties with respect to the subject matter hereof and
supersedes all prior agreements and understandings, oral or written, with respect to such matters. 
  

			
	  

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  



  

 5 








 Exhibit B 
 Certificate of Designations 







 IMMUNOCELLULAR THERAPEUTICS, LTD. 
 CERTIFICATE OF DESIGNATIONS OF PREFERENCES, 
 RIGHTS AND
LIMITATIONS 
 OF 
 SERIES A PREFERRED STOCK 
 The undersigned, Dr. Manish Singh and Dr. John Yu, hereby certify that: 
 1. They are the President and Secretary, respectively, of ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the
“Corporation”). 
 2. The Corporation is authorized to issue 1,000,000 shares of preferred stock, of which no
shares are issued or outstanding. 
 3. The following resolutions were duly adopted by the Board of Directors: 
 WHEREAS, the Certificate of Incorporation of the Corporation provides for a class of its authorized stock known as preferred stock,
comprised of 1,000,000 shares, $0.0001 par value per share (the Preferred Stock”), issuable from time to time in one or more series; 
 WHEREAS, the Board of Directors of the Corporation is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences of
any wholly unissued series of Preferred Stock and the number of shares constituting any series and the designation thereof, of any of them; and 
 WHEREAS, it is the desire of the Board of Directors of the Corporation, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a series of
Preferred Stock, which shall consist of up to 2,000 shares of the Preferred Stock which the Corporation has the authority to issue, as follows: 
 NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of Preferred Stock for cash or exchange of other securities, rights or property and does hereby
fix and determine the rights, preferences, restrictions and other matters relating to such series of Preferred Stock as follows: 
 TERMS OF PREFERRED STOCK 
 1. Designation, Amount and Par Value. The series of Preferred Stock shall be
designated as the Corporation’s Series A Preferred Stock (the “Series A Preferred Stock”) and the number of shares so designated shall be 2,000, which shall not be subject to increase without any consent of the holders of the
Series A Preferred Stock (each a “Holder” and collectively, the “Holders”) that may be required by applicable law. Each share of Series A Preferred Stock shall have a par value of $0.0001 per share. 
  

 1 








 2. Ranking and Voting. 
 a. The Series A Preferred Stock shall, with respect to dividend rights and rights upon liquidation, winding-up or dissolution, rank:

 (i) senior to the Corporation’s common stock, par value $0.0001 per share (“Common Stock”), and any
other class or series of Preferred Stock of the Corporation (except as set forth below) (collectively, together with any warrants, rights, calls or options exercisable for or convertible into such Preferred Stock, the “Junior
Securities”); and 
 (ii) junior to all existing and future indebtedness of the Corporation. 
 b. Except as required by applicable law or as set forth herein, the holders of shares of Series A Preferred Stock will have no right to vote
on any matters, questions or proceedings of this Corporation including, without limitation, the election of directors. 
 3.
Dividends and Other Distributions. Commencing on the date of the issuance of any such shares of Series A Preferred Stock (each respectively an “Issuance Date”), Holders of Series A Preferred Stock shall be entitled to receive
dividends on each outstanding share of Series A Preferred Stock (“Dividends”), which shall accrue in shares of Series A Preferred Stock at a rate equal to 10.0% per annum from the Issuance Date. Accrued Dividends shall
be payable upon redemption of the Series A Preferred Stock in accordance with Section 6. 
 a. Any calculation of
the amount of such Dividends payable pursuant to the provisions of this Section 3 shall be made based on a 365-day year and on the number of days actually elapsed during the applicable period, compounded annually. 
 b. So long as any shares of Series A Preferred Stock are outstanding, no dividends or other distributions will be paid, declared or set
apart with respect to any Junior Securities. The Common Stock shall not be redeemed while the Series A Preferred Stock is outstanding; provided, however, that the foregoing shall not limit the Corporation’s ability to enter into
open market repurchases of its securities, to exercise any repurchase rights the Corporation is entitled to under any of its existing stock options or employment agreements, or to take similar actions. 
 4. Protective Provision. So long as any shares of Series A Preferred Stock are outstanding, the Corporation shall not, without the
affirmative approval of the Holders of a majority of the shares of the Series A Preferred Stock then outstanding (voting as a class), (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter
or amend this Certificate of Designations, (b) authorize or create any class of stock ranking as to distribution of assets upon a liquidation senior to or otherwise pari passu with the Series A Preferred Stock, (c) amend its certificate or
articles of incorporation or other charter documents in breach of any of the provisions hereof, (d) increase the authorized number of shares of Series A Preferred Stock, (e) liquidate, dissolve or wind-up the business and affairs of the
Corporation, or effect any Deemed Liquidation Event (as defined below), or (f) enter into any agreement with respect to the foregoing. 
  

 2 








 a. A “Deemed Liquidation Event” shall mean: (i) a merger or
consolidation in which the Corporation is a constituent party or a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or
consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of
capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of the surviving or resulting corporation or if the surviving or resulting corporation is a wholly owned
subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or (ii) the sale, lease, transfer, exclusive license (other than an exclusive license to a
pharmaceutical or biotech company entered into in the ordinary course of business) or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all
the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its
subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. 
 b. The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in Section 4(a) unless the agreement or
plan of merger or consolidation for such transaction provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with Section 5.

 5. Liquidation. 
 a. Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, after payment or provision for payment of debts and other liabilities of the Corporation, before
any distribution or payment shall be made to the holders of any Junior Securities by reason of their ownership thereof, the Holders of Series A Preferred Stock shall first be entitled to be paid out of the assets of the Corporation available for
distribution to its stockholders an amount with respect to each outstanding share of Series A Preferred Stock equal to $10,000.00 (the “Original Series A Issue Price”), plus any accrued but unpaid Dividends thereon
(collectively, the “Series A Liquidation Value”). If, upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the amounts payable with respect to the shares of Series A Preferred Stock
are not paid in full, the holders of shares of Series A Preferred Stock shall share equally and ratably in any distribution of assets of the Corporation in proportion to the liquidation preference and an amount equal to all accumulated and unpaid
Dividends, if any, to which each such holder is entitled. 
 b. After payment has been made to the Holders of the Series A
Preferred Stock of the full amount of the Series A Liquidation Value, any remaining assets of the Corporation shall be distributed among the holders of the Corporation’s Junior Securities in accordance with the Corporation’s Certificates
of Designation and Certificate of Incorporation. 
  

 3 








 c. If, upon any liquidation, dissolution or winding up of the Corporation, the assets of the
Corporation shall be insufficient to make payment in full to all Holders, then such assets shall be distributed among the Holders at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively
entitled. 
 6. Redemption. 
 a. Corporation’s Redemption Option. Upon or after the fourth anniversary of the initial Issuance Date, the Corporation shall have the right, at the Corporation’s option, to redeem all or
a portion of the shares of Series A Preferred Stock, at a price per share (the “Corporation Redemption Price”) equal to 100% of the Series A Liquidation Value. 
 b. Early Redemption. Prior to redemption pursuant to Section 6(a) hereof, the Corporation shall have the right, at the
Corporation’s option, to redeem all or a portion of the shares of Series A Preferred Stock, at a price per share equal to: (i) 127% of the Series A Liquidation Value if redeemed on or after the first anniversary but prior to the second
anniversary of the initial Issuance Date, (ii) 118% of the Series A Liquidation Value if redeemed on or after the second anniversary but prior to the third anniversary of the initial Issuance Date, and (iii) 109% of the Series A
Liquidation Value if redeemed on or after the third anniversary but prior to the fourth anniversary of the initial Issuance Date. 
 c. Mandatory Redemption. If the Corporation determines to liquidate, dissolve or wind-up its business and affairs, or effect any Deemed Liquidation Event, the Corporation shall redeem the Series B Preferred Stock at the prices set
forth in Section 6(b) including the premium for early redemption set forth therein. 
 d. Mechanics of Redemption.
If the Corporation elects to redeem any of the Holders’ Series A Preferred Stock then outstanding, it shall do so by delivering written notice thereof via facsimile and overnight courier (“Notice of Redemption at Option of
Corporation”) to each Holder, which Notice of Redemption at Option of Corporation shall indicate (A) the number of shares of Series A Preferred Stock that the Corporation is electing to redeem and (B) the Corporation Redemption
Price (plus the premium for early redemption pursuant to Section 6(b) if applicable). 
 e. Payment of Redemption
Price. Upon receipt by any Holder of a Notice of Redemption at Option of Corporation, such Holder shall promptly submit to the Corporation such Holder’s Series A Preferred Stock certificates. Upon receipt of such Holder’s Series A
Preferred Stock certificates, the Corporation shall pay the Corporation Redemption Price (plus the premium for early redemption pursuant to Section 6(b) if applicable), to such Holder, at the Corporation’s option either (i) in
cash, or (ii) by offset against any outstanding note payable from Holder to the Corporation that was issued by Holder in connection with the exercise of warrants by such Holder. 
 7. Transferability. The Series A Preferred Stock may only be sold, transferred, assigned, pledged or otherwise disposed of
(“Transfer”) in accordance with state and federal securities laws. The Corporation shall keep at its principal office, or at the offices of its transfer agent, a register of the Series A Preferred Stock. Upon the surrender of any
certificate

  

 4 








 
representing Series A Preferred Stock at such place, the Corporation, at the request of the record Holder of such certificate, shall execute and deliver (at the Corporation’s expense) a new
certificate or certificates in exchange therefor representing in the aggregate the number of shares represented by the surrendered certificate. Each such new certificate shall be registered in such name and shall represent such number of shares as
is requested by the Holder of the surrendered certificate and shall be substantially identical in form to the surrendered certificate. 
 8. Miscellaneous. 
 a. Notices. Any and all notices to the Corporation shall be addressed to the
Corporation’s President or Chief Executive Officer at the Corporation’s principal place of business on file with the Secretary of State of the State of Delaware. Any and all notices or other communications or deliveries to be provided by
the Corporation to any Holder hereunder shall be in writing and delivered personally, by facsimile, sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile telephone number or address of such Holder
appearing on the books of the Corporation, or if no such facsimile telephone number or address appears, at the principal place of business of the Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective
on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this Section 8 prior to 5:30 p.m. Eastern time, (ii) the date after the
date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this section later than 5:30 p.m. but prior to 11:59 p.m. Eastern time on such date, (iii) the second business day
following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. 
 b. Lost or Mutilated Preferred Stock Certificate. Upon receipt of evidence reasonably satisfactory to the Corporation (an affidavit
of the registered Holder shall be satisfactory) of the ownership and the loss, theft, destruction or mutilation of any certificate evidencing shares of Series A Preferred Stock, and in the case of any such loss, theft or destruction upon receipt of
indemnity reasonably satisfactory to the Corporation (provided that if the Holder is a financial institution or other institutional investor its own agreement shall be satisfactory) or in the case of any such mutilation upon surrender of such
certificate, the Corporation shall, at its expense, execute and deliver in lieu of such certificate a new certificate of like kind representing the number of shares of such class represented by such lost, stolen, destroyed or mutilated certificate
and dated the date of such lost, stolen, destroyed or mutilated certificate. 
 c. Headings. The headings contained
herein are for convenience only, do not constitute a part of this Certificate of Designations and shall not be deemed to limit or affect any of the provisions hereof. 
 RESOLVED, FURTHER, that the chairman, chief executive officer, president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and
directed to prepare and file a Designation of Preferences, Rights and Limitations of Series A Preferred Stock in accordance with the foregoing resolution and the provisions of Delaware law. 
  

 5 








 IN WITNESS WHEREOF, the undersigned have executed this Certificate this 3rd day of December
2009. 
  

									
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  









 Exhibit C 
 Transfer Agent Instructions 







 December 3, 2009 
 Computershare Trust Company, N.A. 
 250 Royall Street 
 Canton, Massachusetts 02021 
 Re:
ImmunoCellular Therapeutics, Ltd. 
 Ladies and Gentlemen: 
 In accordance with the Preferred Stock Purchase Agreement (“Purchase Agreement”), dated December 3, 2009, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation
(“Company”), and Socius Life Sciences Capital Group, LLC, a Delaware limited liability company (“Buyer”), pursuant to which Company may issue and deliver shares (the “Fee Shares”) of the
Company’s common stock, par value $0.0001 per share (“Common Stock”), and a warrant (“Warrant”) to purchase additional shares (“Warrant Shares”) of Common Stock (the Fee Shares and Warrant Shares,
collectively, “Common Shares”), this shall serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time) to issue the Fee Shares and, in the event the holder of
the Warrant elects or has elected to exercise all or any portion of the Warrant, from time to time, upon delivery to you from the Company or its counsel of a notice of exercise of the Warrant, the Warrant Shares. Capitalized terms used herein
without definition shall have the respective meanings ascribed to them in the Purchase Agreement. 
 Specifically, this shall
constitute an irrevocable instruction to you to process any notice of exercise of the Warrant sent to you by the Company or its counsel in accordance with the terms of these instructions as soon as practicable. Upon your receipt of a copy of the
executed notice of exercise of the Warrant from the Company or its counsel, you shall use your best efforts to, within one (1) Trading Day following the date of receipt of the notice of exercise, (A) issue and surrender to a common carrier
for overnight delivery to the address as specified in the notice of exercise a certificate, registered in the name of the Buyer or its designee, for the number of shares of Common Stock to which the Buyer is entitled upon exercise of the Warrant as
set forth in the notice of exercise, or (B) provided you are participating in The Depository Trust Company (DTC) Fast Automated Securities Transfer (FAST) Program, upon the request of the Buyer, credit such aggregate number of shares of Common
Stock to which the Buyer is entitled to the Buyer’s or its designee’s balance account with DTC through its Deposit Withdrawal At Custodian (DWAC) system provided the Buyer causes its bank or broker to initiate the DWAC transaction.

 The Company hereby confirms that, provided a registration statement covering the resale of the Warrant Shares has been
declared effective by the SEC under the Act and remains effective, the Common Shares should not be subject to any stop-transfer restrictions and shall otherwise be freely transferable on the books and records of the Company. If the Common Shares are
certificated, the certificates shall not bear any legend restricting transfer of the shares represented thereby. 
  

 1 








 The Company hereby confirms and you acknowledge that, in the event counsel to the Company
does not issue any opinion of counsel required to issue any Common Shares free of legend, the Company authorizes you to accept an opinion of counsel from Luce Forward Hamilton & Scripps LLP. 
 The Company hereby confirms that no instructions other than as contemplated herein will be given to you by the Company or its counsel (or
any other party) with respect to the Common Shares. The Company hereby agrees that it shall not replace you as the Company’s transfer agent, until such time as the Company provides written notice to you and Buyer that a suitable replacement has
agreed to serve as transfer agent and to be bound by the terms and conditions of this letter agreement regarding Irrevocable Transfer Agent Instructions (this “Agreement”). 
 The Company and you hereby acknowledge and confirm that complying with the terms of this Agreement does not and shall not prohibit you from
satisfying any and all fiduciary responsibilities and duties you may owe to the Company. 
 The Company and you acknowledge that
the Buyer is relying on the representations and covenants made by the Company and you hereunder and that such representations and covenants are a material inducement to the Buyer to enter into the Purchase Agreement. The Company and you further
acknowledge that without such representations and covenants made hereunder, the Buyer would not enter into the Purchase Agreement and purchase Securities pursuant thereto. 
 Each party hereto specifically acknowledges and agrees that a breach or threatened breach of any provision hereof will cause irreparable
damage and that damages at law would be an inadequate remedy if this Agreement were not specifically enforced. Therefore, in the event of a breach or threatened breach by a party hereto, including, without limitation, the attempted termination of
the agency relationship created by this instrument, in addition to all other rights or remedies, an injunction restraining such breach and granting specific performance of the provisions of this Agreement should issue without any requirement to show
any actual damage or to post any bond or other security. 
 You may at any time resign as transfer agent hereunder by giving
thirty (30) days prior written notice of resignation to the Company and the Buyer. Prior to the effective date of the resignation as specified in such notice, the Company will issue to you instructions authorizing delivery of Common Shares to a
substitute transfer agent selected by, and in the sole discretion of, the Company. If no successor transfer agent is named by the Company, you may apply to a court of competent jurisdiction in the State of Delaware for appointment of a successor
transfer agent and for an order to deposit Common Shares with the clerk of any such court. 
  

 2 








 IN WITNESS WHEREOF, the parties have caused this letter agreement regarding Irrevocable
Transfer Agent Instructions to be duly executed and delivered as of the date first written above. 
  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	  

	Name:	 	  

	Title:	 	  



 THE FOREGOING INSTRUCTIONS ARE ACKNOWLEDGED AND AGREED TO: 
  

			
	COMPUTERSHARE TRUST COMPANY, N.A.
		
	By:	 	  

	Name:	 	  

	Title:	 	  









 Exhibit D 
 Opinion 







 December 3, 2009 
 Socius Life Sciences Capital Group, LLC 
 11150 Santa Monica Boulevard, Suite 1500 
 Los Angeles, CA 90025 
  

	Re:	ImmunoCellular Therapeutics, Ltd. 

 Ladies and
Gentlemen: 
 We have acted as counsel to ImmunoCellular Therapeutics, Ltd., a Delaware corporation (“the
Company”), in connection with the sale and issuance of up to 1000 shares of Series A Preferred Stock, par value $0.0001 per share (“Preferred Shares”), along with shares (“Fee Shares”) of the Company’s
common stock, par value $0.0001 per share (“Common Stock”), and warrant (“Warrant”) to purchase additional shares of Common Stock, to Socius Capital Group, LLC, dba Socius Life Sciences Capital Group, LLC, a
Delaware limited liability company (“Investor”), pursuant to the terms of the Preferred Stock Purchase Agreement, dated as of December 3, 2009 (“Agreement”), by and between Company and Investor. Capitalized
terms used in this opinion, that are not otherwise defined in this opinion, shall have the respective meanings assigned to them in the Agreement. This opinion is being delivered to you pursuant to the Agreement. 
 We are of the opinion that, as of the date hereof: 
 1. Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. 
 2. The Securities are duly authorized, the Preferred Shares, Fee Shares and Warrant are, and when issued in accordance with the terms and conditions of the Agreement the Warrant Shares will be, validly
issued, fully paid and non-assessable. The issuance of the Securities will not be subject to any statutory or contractual preemptive rights of any stockholder of the Company. 
 3. Company has the corporate power and authority to (a) execute, deliver and perform all of its obligations under the Agreement and the
Transaction Documents, and (b) issue, sell and deliver each of the Securities. 
 4. The execution, delivery and
performance of the Agreement and the Transaction Documents have been duly authorized by all necessary corporate action on the part of Company, and have been duly executed and delivered by Company. 
  

 1 








 5. The execution and delivery of the Transaction Documents by Company does not, and
Company’s performance of its obligations thereunder will not (a) violate the certificate or articles of incorporation or the by-laws of Company, as in effect on the date hereof, (b) violate in any material respect any federal or state
law, rule or regulation, or judgment, order or decree of any state or federal court or governmental or administrative authority, in each case that, to our knowledge, is applicable to Company or its properties or assets and which could have a
material adverse effect on Company’s business, properties, assets, financial condition or results of operations or prevent the performance by Company of any material obligation under the Agreement, or (c) require the authorization,
consent, approval of or other action of, notice to or filing or qualification with, any state or federal governmental authority, except as have been, or will be, made or obtained. 
  

 2 








 Exhibit E 
 Use of Proceeds Certificate 







 IMMUNOCELLULAR THERAPEUTICS, LTD. 
 USE OF PROCEEDS CERTIFICATE 
 The undersigned,
[                    ] and
[                    ], hereby certify that: 
 1. They are the [                    ] and
[                    ], respectively, of ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”). 
 2. This Use of Proceeds Certificate (this “Certificate”) is being delivered to Socius Capital Group, LLC doing business as Socius
Life Sciences Capital Group, LLC (“Investor”), by the Company, to fulfill the requirement under Section 2.3(d)(iii) of the Preferred Stock Purchase Agreement, dated as of December 3 , 2009, between Investor and the Company (the
“Purchase Agreement”). Terms used and not defined in this Certificate have the meanings set forth in the Purchase Agreement. 
 3. On or prior to the date hereof, the Company has delivered to Investor a Tranche Notice for the purchase by Investor of Tranche Shares upon payment by the Company to Investor of the Tranche Purchase Price. 
 The undersigned do hereby certify that the Tranche Purchase Price will be used for the following purpose or purposes: 
 [                            ]. 
 IN WITNESS WHEREOF, the undersigned have executed this Certificate this [    ] day of
            , 2009. 
  

									
	  
	 		 	  

					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  









 Exhibit F 
 Tranche Notice 







 Dated: [            ],
20[    ] 
 Socius Life Sciences Capital Group, LLC 
 11150 Santa Monica Boulevard, Suite 1500 
 Los Angeles, CA 90025 
  

	 	Re:	Tranche Notice 

 Ladies & Gentlemen:

 Pursuant to the December 3, 2009 Preferred Stock Purchase Agreement (“Agreement”) between
ImmunoCellular Therapeutics, Ltd., a Delaware corporation (“Company”), and Socius Life Sciences Capital Group, LLC (“Investor”), Company hereby elects to exercise a Tranche. Capitalized terms not otherwise defined
herein shall have the meanings defined in the Agreement. 
 At the Tranche Closing, Company will sell to Investor
[                    ] Preferred Shares at $10,000.00 per share for a Tranche Amount of
$[        ]. 
 On behalf of Company, the undersigned hereby certifies to
Investor as follows: 
 1. The undersigned is a duly authorized officer of Company; 
 2. The above Tranche Amount does not exceed the Maximum Tranche Amount; and 
 3. All of the conditions precedent to the right of the Company to deliver a Tranche Notice set forth in Section 2.3(d) of the
Agreement have been satisfied. 
 IN WITNESS WHEREOF, the Company has executed and delivered this Tranche Notice as of the date
first written above. 
  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	  

	Name:	 	  

	Title: